US759A
(en)
|
|
1838-05-30 |
|
Reacting watek-wheels |
US5516A
(en)
|
|
1848-04-18 |
|
Combining lantebns and lamps |
US1015498A
(en)
|
1911-03-01 |
1912-01-23 |
Edward L Kraus |
Folding-desk blackboard.
|
IT535124A
(zh)
|
1952-09-20 |
|
|
|
GB1309692A
(en)
|
1970-02-13 |
1973-03-14 |
Ucb Sa |
N-substituted lactams
|
GB1039113A
(en)
|
1964-08-06 |
1966-08-17 |
Ucb Sa |
New n-substituted lactams
|
US3539573A
(en)
|
1967-03-22 |
1970-11-10 |
Jean Schmutz |
11-basic substituted dibenzodiazepines and dibenzothiazepines
|
JP2000319257A
(ja)
|
1969-01-06 |
2000-11-21 |
Eisai Co Ltd |
1−ベンジル−4−[(5,6−ジメトキシ−2−フルオロ−1−インダノン)−2−イル]メチルピペリジン
|
US3953603A
(en)
|
1973-11-05 |
1976-04-27 |
Eli Lilly And Company |
Hexahydro-dibenzo[b,d,]pyran-9-ones as psychotropic, particularly anti-depressant drugs
|
US4018895A
(en)
|
1974-01-10 |
1977-04-19 |
Eli Lilly And Company |
Aryloxyphenylpropylamines in treating depression
|
IT1045043B
(it)
|
1975-08-13 |
1980-04-21 |
Isf Spa |
Derivati pirrolidinici
|
NL7605526A
(nl)
|
1976-05-24 |
1977-11-28 |
Akzo Nv |
Nieuwe tetracyclische derivaten.
|
IT1075280B
(it)
|
1977-02-11 |
1985-04-22 |
Isf Spa |
Procedimento per la preparazione di derivati pirrolidinici
|
BE864269A
(fr)
|
1977-03-03 |
1978-06-16 |
Parke Davis & Co |
Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
|
JPS54130587A
(en)
|
1978-03-30 |
1979-10-09 |
Otsuka Pharmaceut Co Ltd |
Carbostyryl derivative
|
DE2960194D1
(en)
|
1978-05-08 |
1981-04-16 |
Ucb Sa |
Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
|
US4654370A
(en)
|
1979-03-12 |
1987-03-31 |
Abbott Laboratories |
Glyceryl valproates
|
US4352807A
(en)
|
1979-07-30 |
1982-10-05 |
Pfizer Inc. |
Hexahydro-trans-pyridoindole neuroleptic agents
|
US4337250A
(en)
|
1979-07-30 |
1982-06-29 |
Pfizer Inc. |
Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
|
US4431649A
(en)
|
1979-07-30 |
1984-02-14 |
Pfizer Inc. |
Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
|
US4465683A
(en)
|
1979-09-14 |
1984-08-14 |
Mead Johnson & Company |
Anti-psychotic agents
|
US4254124A
(en)
|
1979-09-24 |
1981-03-03 |
Mead Johnson & Company |
Antidepressant agent
|
US4372960A
(en)
|
1980-12-12 |
1983-02-08 |
Warner-Lambert Company |
Quaternary derivatives of N-(substituted-aminoalkyl)-2-oxo-1-pyrrolidine-acetamides as cognition activators
|
US4427679A
(en)
|
1981-01-16 |
1984-01-24 |
Pfizer Inc. |
Hexahydro-trans- and tetrahydropyridoindole neuroleptic agents
|
FR2515179A1
(fr)
|
1981-07-24 |
1983-04-29 |
Hoffmann La Roche |
Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
|
US4415085A
(en)
|
1981-12-21 |
1983-11-15 |
Eli Lilly And Company |
Dry pharmaceutical system
|
PT77267B
(en)
|
1982-09-07 |
1986-03-21 |
Lilly Co Eli |
Improved process for preparing novel octahydrobenz <f> isoquinolines or compounds relating thereto
|
GR81301B
(zh)
|
1982-09-07 |
1984-12-11 |
Lilly Co Eli |
|
US4476307A
(en)
|
1982-09-20 |
1984-10-09 |
Pfizer Inc. |
Heteroylidene indolone compounds
|
US4879391A
(en)
|
1982-09-20 |
1989-11-07 |
Pfizer Inc. |
1-Phenyl-2(1H,3H)-indolone psychotherapeutic agents
|
US4977178A
(en)
|
1982-09-20 |
1990-12-11 |
Pfizer Inc. |
Method of treating anxiety and depression with 1-phenyl-2(1H,3H)-indolone psycho-therapeutic agents
|
US4495187A
(en)
|
1982-10-18 |
1985-01-22 |
Pfizer Inc. |
Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
|
IL67623A
(en)
|
1983-01-05 |
1984-09-30 |
Teva Pharma |
1'-ethoxycarbonyloxyethyl ester of valproic acid,its preparation and pharmaceutical compositions containing it
|
IL72381A
(en)
|
1983-07-20 |
1988-03-31 |
Sanofi Sa |
Pharmaceutical composition based on valproic acid
|
US4547501A
(en)
|
1983-09-02 |
1985-10-15 |
Pfizer Inc. |
Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents
|
US4599339A
(en)
|
1983-09-26 |
1986-07-08 |
Eli Lilly And Company |
Use of pyrimido[4,5-g]quinolines in treating parkinsonism
|
US4558070A
(en)
|
1983-10-26 |
1985-12-10 |
Abbott Laboratories |
Acid salts of valproic acid
|
US4605655A
(en)
|
1984-03-06 |
1986-08-12 |
Bristol-Myers Company |
Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
|
GB8412357D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
GB8412358D0
(en)
|
1984-05-15 |
1984-06-20 |
Ucb Sa |
Pharmaceutical composition
|
US4668687A
(en)
|
1984-07-23 |
1987-05-26 |
Bristol-Myers Company |
Psychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
|
US4593037A
(en)
|
1984-07-26 |
1986-06-03 |
Pfizer Inc. |
1,3-disubstituted piperidine compounds as neuroleptic agents
|
US4619930A
(en)
|
1985-01-16 |
1986-10-28 |
Bristol-Myers Company |
Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
|
US4913906B1
(en)
|
1985-02-28 |
2000-06-06 |
Yissum Res Dev Co |
Controlled release dosage form of valproic acid
|
IL74497A
(en)
|
1985-03-05 |
1990-02-09 |
Proterra Ag |
Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
|
US4804663A
(en)
|
1985-03-27 |
1989-02-14 |
Janssen Pharmaceutica N.V. |
3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
|
IE58370B1
(en)
|
1985-04-10 |
1993-09-08 |
Lundbeck & Co As H |
Indole derivatives
|
US4656173A
(en)
|
1985-04-24 |
1987-04-07 |
Bristol-Myers Company |
Antipsychotic benzisothiazole S-oxide compound
|
US4677104A
(en)
|
1985-05-06 |
1987-06-30 |
Bristol-Myers Company |
Antipsychotic fused-ring pyridinylpiperazine derivatives
|
JPS6222785A
(ja)
|
1985-07-23 |
1987-01-30 |
Sanwa Kagaku Kenkyusho:Kk |
新規な2−オキソピロリジン化合物及びその塩、その製法並びにこれらを有効成分とする脳機能障害の予防及び治療剤
|
US4663318A
(en)
|
1986-01-15 |
1987-05-05 |
Bonnie Davis |
Method of treating Alzheimer's disease
|
GB8607684D0
(en)
|
1986-03-27 |
1986-04-30 |
Ici America Inc |
Thiazepine compounds
|
IT1190133B
(it)
|
1986-06-19 |
1988-02-10 |
Chiesi Farma Spa |
Derivati di acido valproico e di acido (e)-2-valproenoico,procedimento per la loro preparazione e relative composizioni farmaceutiche
|
US4757073A
(en)
|
1986-09-30 |
1988-07-12 |
Bristol-Myers Company |
Antipsychotic cyclic imide derivatives of 2-(4-butylipiperazin-1-yl) pyridines, compositions and use
|
US4816456A
(en)
|
1986-10-01 |
1989-03-28 |
Summers William K |
Administration of monoamine acridines in cholinergic neuronal deficit states
|
DD263531A5
(de)
|
1986-10-21 |
1989-01-04 |
������@���Kk�� |
Verfahren zur herstellung von verbrueckten bicyclischen imidverbindungen
|
EP0363415B1
(en)
|
1987-05-04 |
2008-10-15 |
Davis, Bonnie |
Compounds for the treatment of alzheimer's disease
|
MX174210B
(es)
|
1987-02-17 |
1994-04-28 |
Pfizer |
Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos
|
US4771053A
(en)
|
1987-03-02 |
1988-09-13 |
Bristol-Myers Company |
Method for alleviation of primary depressive disorders
|
MX173362B
(es)
|
1987-03-02 |
1994-02-23 |
Pfizer |
Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
|
NL195004C
(nl)
|
1987-03-04 |
2003-11-04 |
Novartis Ag |
Fenylcarbamaat bevattend farmaceutisch preparaat.
|
NZ223875A
(en)
|
1987-03-17 |
1991-01-29 |
Hoechst Roussel Pharma |
9-aminotetrahydroacridines and related homologues and pharmaceutical compositions
|
DE3709230A1
(de)
|
1987-03-20 |
1988-10-06 |
Desitin Arzneimittel Gmbh |
Neues calciumsalz der valproinsaeure
|
IT1225462B
(it)
|
1987-04-03 |
1990-11-14 |
Mediolanum Farmaceutici Srl |
Sali organici di derivati della fisostigmina
|
US4784998A
(en)
|
1987-04-06 |
1988-11-15 |
Bristol-Myers Company |
1,3,4-oxadiazole pyschotropic compounds
|
US5002955A
(en)
|
1987-04-23 |
1991-03-26 |
Hoechst-Roussel Pharmaceuticals Inc. |
Fused heteroalkylene quinolinamines and use as cholinergic agents
|
US5187165A
(en)
|
1987-05-15 |
1993-02-16 |
Hoechst-Roussel Pharmaceuticals Inc. |
Memory enhancing and analgesic 1,2,3a,8,8a-hexahydro-3a,8(and 1,3a,8)-di(and tri)methylpyrrolo[2,3-b]indoles
|
US4931447A
(en)
|
1987-06-15 |
1990-06-05 |
Eli Lilly And Company |
Cycloalkylamides of (8β)-1-alkyl-6-(substituted) ergolines
|
FI95572C
(fi)
|
1987-06-22 |
1996-02-26 |
Eisai Co Ltd |
Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
|
JPS6422883A
(en)
|
1987-07-17 |
1989-01-25 |
Sanwa Kagaku Kenkyusho Co |
1-pyrrolidine acetamide derivative, its salt, production thereof and prophylactic and remedial agent for cereral dysfunction containing said derivative and salt as active ingredient
|
EP0300111B1
(en)
|
1987-07-22 |
1991-10-16 |
Farvalsa AG |
A moisture stable solid valproic acid formulation and a method of preparing the same
|
IL87674A
(en)
|
1987-09-08 |
1993-08-18 |
Lilly Co Eli |
Azabicycloalkyl esters and amides of heterocyclic acids, their preparation and pharmaceutical compositions containing them
|
US5364863A
(en)
|
1987-09-08 |
1994-11-15 |
Eli Lilly And Company |
Specific 5-HT3 antagonists
|
US4880930A
(en)
|
1987-11-30 |
1989-11-14 |
New James S |
Psychotropic acyclic amide derivatives
|
US4891375A
(en)
|
1988-01-13 |
1990-01-02 |
Pfizer Inc. |
Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds
|
US4831031A
(en)
|
1988-01-22 |
1989-05-16 |
Pfizer Inc. |
Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
|
US4883795A
(en)
|
1988-01-22 |
1989-11-28 |
Pfizer Inc. |
Piperazinyl-heterocyclic compounds
|
US5001130A
(en)
|
1988-02-18 |
1991-03-19 |
Bristol-Myers Company |
Psychotropic heterobicycloalkylpiperazine derivatives
|
US5238959A
(en)
|
1988-04-08 |
1993-08-24 |
Eli Lilly And Company |
3-phenyloxy-3-phenyl propanamines
|
US5242911A
(en)
|
1988-06-17 |
1993-09-07 |
Pfizer Inc. |
Bridged bicyclic imides as anxiolytics and antidepressants
|
US5077295A
(en)
|
1988-09-16 |
1991-12-31 |
Pfizer Inc. |
Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
|
US5006528A
(en)
|
1988-10-31 |
1991-04-09 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives
|
US5254556A
(en)
|
1988-11-07 |
1993-10-19 |
Janssen Pharmaceutica N.V. |
3-piperidinyl-1,2-benzisoxazoles
|
CA2000786C
(en)
|
1988-11-07 |
1999-01-26 |
Cornelus G. M. Janssen |
3-piperidinyl-1,2-benzisoxazoles
|
US5158952A
(en)
|
1988-11-07 |
1992-10-27 |
Janssen Pharmaceutica N.V. |
3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
|
MX18467A
(es)
|
1988-11-23 |
1993-07-01 |
Pfizer |
Agentes terapeuticos de quinuclidinas
|
WO1990006303A1
(en)
|
1988-12-02 |
1990-06-14 |
Pfizer Inc. |
Arylpiperidine derivatives
|
US4950658A
(en)
|
1988-12-06 |
1990-08-21 |
Board Of Trustees Of Southern Illinois Univ. |
Method of medical treatment of Alzheimer's disease
|
HUT53607A
(en)
|
1989-01-17 |
1990-11-28 |
Hoffmann La Roche |
Process for production of derivatives of cyclohexan-acetamid
|
WO1990007926A1
(en)
|
1989-01-20 |
1990-07-26 |
Pfizer Inc. |
3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridines
|
FR2643556B1
(fr)
|
1989-02-27 |
1993-03-05 |
Sanofi Sa |
Composition pharmaceutique a liberation prolongee d'acide valproique
|
US4981870A
(en)
|
1989-03-07 |
1991-01-01 |
Pfizer Inc. |
Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
|
GB8908085D0
(en)
|
1989-04-11 |
1989-05-24 |
Lundbeck & Co As H |
New therapeutic use
|
US5238945A
(en)
|
1989-04-11 |
1993-08-24 |
H. Lundbeck A/S |
Method of treating psychoses
|
US4914207A
(en)
|
1989-05-09 |
1990-04-03 |
Pfizer Inc. |
Arylthiazolylimidazoles
|
US4963689A
(en)
|
1989-05-19 |
1990-10-16 |
Pfizer Inc. |
Heterocyclicguanidines as 5HT3 antagonists
|
ES2076253T3
(es)
|
1989-05-19 |
1995-11-01 |
Hoechst Roussel Pharma |
N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
|
US5364866A
(en)
|
1989-05-19 |
1994-11-15 |
Hoechst-Roussel Pharmaceuticals, Inc. |
Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
|
US5693668A
(en)
|
1989-06-22 |
1997-12-02 |
Merrell Pharmaceuticals Inc. |
Acetylcholinesterase inhibitors
|
EP0403713A1
(en)
|
1989-06-22 |
1990-12-27 |
Merrell Dow Pharmaceuticals Inc. |
Novel acetylcholinesterase inhibitors
|
WO1991000863A1
(en)
|
1989-07-07 |
1991-01-24 |
Pfizer Inc. |
Heteroaryl piperazine antipsychotic agents
|
US5350747A
(en)
|
1989-07-07 |
1994-09-27 |
Pfizer Inc |
Heteroaryl piperazine antipsychotic agents
|
IT1231477B
(it)
|
1989-07-12 |
1991-12-07 |
Sigma Tau Ind Farmaceuti |
(pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
|
US5006525A
(en)
|
1989-07-24 |
1991-04-09 |
Eli Lilly And Company |
Dopamine agonists method
|
US4956368A
(en)
|
1989-07-24 |
1990-09-11 |
Bristol-Myers Company |
Metabolites and prodrug formulations of 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione
|
US4999430A
(en)
|
1989-07-31 |
1991-03-12 |
Warner-Lambert Company |
Derivatives of 1,2,3,4-tetrahydro-9-acrisinamine
|
DE3927049A1
(de)
|
1989-08-16 |
1991-02-21 |
Sandoz Ag |
Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
|
US5387590A
(en)
|
1989-08-30 |
1995-02-07 |
Pfizer Inc. |
Benzazabicyclic carbamates as novel cholinesterase inhibitors
|
US4914102A
(en)
|
1989-09-28 |
1990-04-03 |
Hoechst Roussel Pharmaceuticals, Inc. |
N-aminocarbamates related to physostigmine, pharmacentical compositions and use
|
US5011841B1
(en)
|
1989-11-14 |
1994-09-06 |
Pfizer |
Treatment of depression
|
UA41251C2
(uk)
|
1990-01-04 |
2001-09-17 |
Пфайзер, Інк. |
Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
|
US5232929A
(en)
|
1990-11-28 |
1993-08-03 |
Pfizer Inc. |
3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
|
NZ237241A
(en)
|
1990-03-02 |
1993-11-25 |
Pharmetrix Corp |
Method for increasing the storage stability of physostigmine
|
US5043341A
(en)
|
1990-04-11 |
1991-08-27 |
Eli Lilly And Company |
N-(2-hydroxycyclopentyl)-1-isopropyl-6-methylergoline-8-carboxamides
|
US5229382A
(en)
|
1990-04-25 |
1993-07-20 |
Lilly Industries Limited |
2-methyl-thieno-benzodiazepine
|
JPH072740B2
(ja)
|
1990-06-01 |
1995-01-18 |
フアイザー・インコーポレイテツド |
3―アミノ―2―アリールキヌクリジン
|
JP2807577B2
(ja)
|
1990-06-15 |
1998-10-08 |
エーザイ株式会社 |
環状アミド誘導体
|
JP2800953B2
(ja)
|
1990-07-06 |
1998-09-21 |
住友製薬株式会社 |
新規なイミド誘導体
|
US5399565A
(en)
|
1990-07-17 |
1995-03-21 |
Eli Lilly And Company |
Pyrazolidinone CCK and gastrin antagonists and pharmaceutical formulations therof
|
BR9106665A
(pt)
|
1990-07-23 |
1993-06-08 |
Pfizer |
Derivados de quinuclidina
|
US5102891A
(en)
|
1990-07-23 |
1992-04-07 |
Hoechst-Roussel Pharmaceuticals Inc. |
1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates
|
US5264442A
(en)
|
1990-08-13 |
1993-11-23 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Carbamoyl-1-(pyridinylalkyl)-1H-indoles, indolines and related analogs
|
TW200462B
(zh)
|
1990-09-27 |
1993-02-21 |
Hoechst Roussel Pharma |
|
AU651145B2
(en)
|
1990-09-28 |
1994-07-14 |
Pfizer Inc. |
Fused ring analogs of nitrogen containing nonaromatic heterocycles
|
WO1992006973A1
(en)
|
1990-10-15 |
1992-04-30 |
Pfizer Inc. |
Indole derivatives
|
US5578612A
(en)
|
1990-10-15 |
1996-11-26 |
Pfizer Inc. |
Indole derivatives
|
US5559129A
(en)
|
1990-10-15 |
1996-09-24 |
Pfizer Inc |
Indole derivatives
|
US5190951A
(en)
|
1990-10-19 |
1993-03-02 |
Ss Pharmaceutical Co., Ltd. |
Quinoline derivatives
|
US5147881A
(en)
|
1990-11-14 |
1992-09-15 |
Pfizer Inc |
4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
|
JP2965675B2
(ja)
|
1990-11-21 |
1999-10-18 |
エーザイ株式会社 |
(―)―1―ベンジル―4―〔(5,6―ジメトキシ―1―インダノン)―2―イル〕メチルピペリジンの製造方法
|
TW197435B
(zh)
|
1990-11-22 |
1993-01-01 |
Takeda Pharm Industry Co Ltd |
|
JPH04327532A
(ja)
|
1991-01-31 |
1992-11-17 |
Bristol Myers Squibb Co |
活動過剰を伴う注意力欠乏疾患の治療に使用する医薬製剤
|
US5668117A
(en)
|
1991-02-22 |
1997-09-16 |
Shapiro; Howard K. |
Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
|
US5157034A
(en)
|
1991-02-27 |
1992-10-20 |
Pfizer Inc. |
Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
|
WO1992015585A1
(en)
|
1991-03-01 |
1992-09-17 |
Pfizer Inc. |
1-azabicyclo[3.2.2]nonan-3-amine derivatives
|
US5334720A
(en)
|
1991-03-07 |
1994-08-02 |
Fisons Corporation |
Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
|
US5750542A
(en)
|
1993-09-28 |
1998-05-12 |
Pfizer |
Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
|
CA2195129C
(en)
|
1991-03-28 |
2002-09-10 |
Anabella Villalobos |
Substituted piperidine intermediates for producing heterocyclic-cyclic amine derivatives capable of inhibiting cholinesterase
|
US5817656A
(en)
|
1991-04-23 |
1998-10-06 |
Eli Lilly And Company |
Mental disorders
|
US5627178A
(en)
|
1991-04-23 |
1997-05-06 |
Lilly Industries Limited |
2-methyl-thieno-benzodiazepine
|
US5817655A
(en)
|
1991-04-23 |
1998-10-06 |
Eli Lilly And Company |
Methods of treatment using a thieno-benzodiazepine
|
US5104880A
(en)
|
1991-05-01 |
1992-04-14 |
Mayo Foundation For Medical Education And Research |
Huperzine a analogs as acetylcholinesterase inhibitors
|
SK279285B6
(sk)
|
1991-05-02 |
1998-09-09 |
Daiichi Pharmaceutical Co. |
Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
|
US5716965A
(en)
|
1991-05-22 |
1998-02-10 |
Pfizer Inc. |
Substituted 3-aminoquinuclidines
|
FR2677019B1
(fr)
|
1991-05-27 |
1994-11-25 |
Pf Medicament |
Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique.
|
DE9290063U1
(de)
|
1991-05-31 |
1994-02-24 |
Pfizer Inc., New York, N.Y. |
Chinuclidin-Derivate
|
US5106856A
(en)
|
1991-06-07 |
1992-04-21 |
Hoechst-Roussel Pharmaceuticals Inc. |
[(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds
|
WO1993000331A1
(en)
|
1991-06-20 |
1993-01-07 |
Pfizer Inc. |
Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
|
TW202432B
(zh)
|
1991-06-21 |
1993-03-21 |
Pfizer |
|
FR2679555B1
(fr)
|
1991-07-25 |
1993-11-19 |
Fabre Medicament Pierre |
Nouveaux derives de l'uree, leur preparation et leur application en therapeutique.
|
JPH06509576A
(ja)
|
1991-07-29 |
1994-10-27 |
ワーナー−ランバート・コンパニー |
アセチルコリンエステラーゼ阻害剤としてのキナゾリン誘導体
|
IT1251166B
(it)
|
1991-08-09 |
1995-05-04 |
Chiesi Farma Spa |
Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
|
US5161533A
(en)
|
1991-09-19 |
1992-11-10 |
Xomed-Treace Inc. |
Break-apart needle electrode system for monitoring facial EMG
|
US5246947A
(en)
|
1991-09-23 |
1993-09-21 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Substituted pyridinylamino-1,2-benzisothiazoles and their use for treating depression
|
ATE146178T1
(de)
|
1991-09-25 |
1996-12-15 |
Pfizer |
Neuroleptisch 2-substituierte perhydro-1h- pyrido(1,2-a>pyrazine
|
DK0607164T3
(da)
|
1991-09-26 |
2002-06-17 |
Pfizer |
Kondenserede tricykliske nitrogenholdige heterocykliske forbindelser som substans P-receptorantagonister
|
US5231093A
(en)
|
1991-10-01 |
1993-07-27 |
Hoechst-Roussel Pharmaceuticals Incorporated |
Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
|
TW263504B
(zh)
|
1991-10-03 |
1995-11-21 |
Pfizer |
|
CA2080536A1
(en)
|
1991-10-17 |
1993-04-18 |
John S. Ward |
Nicotinic activity of a series of arecolones and isoarecolones
|
US5710168A
(en)
|
1991-10-23 |
1998-01-20 |
Pfizer Inc. |
2-piperidino-1-alkanol derivatives as neuroprotective agents
|
EP0613458B1
(en)
|
1991-11-12 |
1998-01-07 |
Pfizer Inc. |
Acyclic ethylenediamine derivatives as substance p receptor antagonists
|
EP0619805B1
(en)
|
1991-11-25 |
2000-03-15 |
Pfizer Inc. |
5-(hetero- or carbocyclylamino)-indole derivatives, their preparation and their use as 5-ht1 agonists
|
US5137894A
(en)
|
1991-12-05 |
1992-08-11 |
New James S |
4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
|
ES2042384B1
(es)
|
1991-12-26 |
1994-06-01 |
Boehringer Ingelheim Espana |
Procedimiento para obtener derivados bis-piridinicos.
|
AU3171493A
(en)
|
1991-12-31 |
1993-07-28 |
Fujisawa Pharmaceutical Co., Ltd. |
Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
|
CA2129732A1
(en)
|
1992-02-25 |
1993-09-02 |
Alain Martin |
Cytoprotective compositions containing pyruvate and antioxidants
|
TW288010B
(zh)
|
1992-03-05 |
1996-10-11 |
Pfizer |
|
US5569662A
(en)
|
1992-03-23 |
1996-10-29 |
Pfizer Inc. |
Quinuclidine derivatives as substance P antagonists
|
US6380233B1
(en)
|
1992-04-07 |
2002-04-30 |
Pfizer Inc |
Indole derivatives as 5-HT1 agonists
|
US5747501A
(en)
|
1992-04-07 |
1998-05-05 |
Pfizer, Inc. |
Indole derivatives
|
UA34452C2
(uk)
|
1992-04-10 |
2001-03-15 |
Пфайзер Інк. |
Похідні ациламіноіндолу, що проявляють серотонінову 5-нт1 агоністичну активність та похідні аміноіндолу як проміжні сполуки
|
US5439930A
(en)
|
1992-04-14 |
1995-08-08 |
Russian-American Institute For New Drug Development |
Biologically active n-acylprolydipeptides having antiamnestic, antihypoxic and anorexigenic effects
|
US5256664A
(en)
|
1992-04-28 |
1993-10-26 |
Bristol-Myers Squibb Company |
Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
|
US20050256162A1
(en)
|
1992-05-05 |
2005-11-17 |
Pfizer Inc |
Fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
|
EP0641328B1
(en)
|
1992-05-18 |
2001-11-21 |
Pfizer Inc. |
Bridged aza-bicyclic derivatives as substance p antagonists
|
IT1254996B
(it)
|
1992-06-25 |
1995-10-11 |
Mediolanum Farmaceutici Srl |
Esteri amminoalchilcarbammici dell'eserolina atti all'impiego come anticolinesterasici e relativo procedimento di preparazione
|
US5688804A
(en)
|
1992-08-04 |
1997-11-18 |
Pfizer Inc. |
3-Benzylamino-2-phenyl-piperidine derivatives as substance P receptor antagonists
|
DE69331103T2
(de)
|
1992-08-19 |
2002-03-14 |
Pfizer |
Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
|
US5312925A
(en)
|
1992-09-01 |
1994-05-17 |
Pfizer Inc. |
Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
|
US5440023A
(en)
|
1992-09-18 |
1995-08-08 |
Beckman Instruments, Inc. |
Method for making valproic acid derivatives
|
US5604241A
(en)
|
1992-10-21 |
1997-02-18 |
Pfizer Inc. |
Substituted benzylaminoquinuclidines as substance P antagonists
|
US5837711A
(en)
|
1992-10-28 |
1998-11-17 |
Pfizer Inc. |
Substituted quinuclidines as substance P antagonists
|
TW251284B
(zh)
|
1992-11-02 |
1995-07-11 |
Pfizer |
|
US5498610A
(en)
|
1992-11-06 |
1996-03-12 |
Pfizer Inc. |
Neuroprotective indolone and related derivatives
|
AU676489B2
(en)
|
1992-11-12 |
1997-03-13 |
Pfizer Inc. |
Quinuclidine derivative as substance P antagonist
|
WO1994013663A1
(en)
|
1992-12-10 |
1994-06-23 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
|
US6369074B1
(en)
|
1992-12-10 |
2002-04-09 |
Pfizer Inc. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
US5352459A
(en)
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
TW444018B
(en)
|
1992-12-17 |
2001-07-01 |
Pfizer |
Pyrazolopyrimidines
|
JP2895961B2
(ja)
|
1992-12-17 |
1999-05-31 |
フアイザー・インコーポレイテツド |
Crfアンタゴニストとしてのピロロピリミジン
|
EP0611769A1
(en)
|
1993-02-16 |
1994-08-24 |
Merrell Dow Pharmaceuticals Inc. |
Silylated acetylcholinesterase inhibitors
|
AU4982293A
(en)
|
1993-03-02 |
1994-09-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel heterocyclic compound
|
EP0687268B1
(en)
|
1993-03-04 |
1998-05-27 |
Pfizer Inc. |
Spiroazacyclic derivatives as substance p antagonists
|
JP2810236B2
(ja)
|
1993-03-16 |
1998-10-15 |
フアイザー・インコーポレイテツド |
ナフタレン誘導体
|
IL109646A0
(en)
|
1993-05-19 |
1994-08-26 |
Pfizer |
Heteroatom substituted alkyl benzylamino-quinuclidines
|
EP0627400A1
(en)
|
1993-06-04 |
1994-12-07 |
Merrell Dow Pharmaceuticals Inc. |
Aromatic acetylcholinesterase inhibitors
|
SE9302080D0
(sv)
|
1993-06-16 |
1993-06-16 |
Ab Astra |
New compounds
|
ATE171945T1
(de)
|
1993-07-15 |
1998-10-15 |
Pfizer |
Benzyloxychinuclidine als substanz p antagonisten
|
CZ59996A3
(en)
|
1993-08-31 |
1996-06-12 |
Pfizer |
5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
|
JP2963200B2
(ja)
|
1993-09-17 |
1999-10-12 |
ファイザー・インク. |
ヘテロアリールアミノおよびヘテロアリールスルホンアミド置換3−ベンジルアミノメチルピペリジン類および関連化合物
|
US6083943A
(en)
|
1993-09-17 |
2000-07-04 |
Pfizer Inc |
Substituted azaheterocyclecarboxylic acid
|
GB9319732D0
(en)
|
1993-09-24 |
1993-11-10 |
Ucb Sa |
Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety
|
US5468733A
(en)
|
1993-09-30 |
1995-11-21 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
CA2180263C
(en)
|
1993-12-29 |
2000-05-16 |
Harry R. Howard, Jr. |
Diazabicyclic neurokinin antagonists
|
ATE167057T1
(de)
|
1994-03-02 |
1998-06-15 |
Akzo Nobel Nv |
Sublinguales oder bukkales arzneimittel
|
DE69533284T2
(de)
|
1994-04-29 |
2005-07-21 |
Pfizer Inc. |
Neue cyclische und acyclische amide zur erhöhung der neurotransmitter ausschüttung
|
WO1995034563A1
(en)
|
1994-06-16 |
1995-12-21 |
Pfizer Inc. |
Pyrazolo and pyrrolopyridines
|
US5744476A
(en)
|
1994-06-27 |
1998-04-28 |
Interneuron Pharmaceuticals, Inc. |
Dopamine D1 agonists for the treatment of dementia
|
MX9700080A
(es)
|
1994-06-29 |
1997-04-30 |
Pfizer |
Derivados de aril y heteroaril alcoxinaftaleno.
|
CA2194984C
(en)
|
1994-07-26 |
2002-07-02 |
John Eugene Macor |
4-indole derivatives as serotonin agonists and antagonists
|
PT777652E
(pt)
|
1994-08-18 |
2003-11-28 |
Pfizer |
Derivados neuroptotectores de 3-(piperidinil-1)-croman-4.7-diol e de 1-(4-hidrofenil)-2-(piperidinil-1)-alcanol
|
US5597826A
(en)
|
1994-09-14 |
1997-01-28 |
Pfizer Inc. |
Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
|
US5627200A
(en)
|
1994-09-26 |
1997-05-06 |
Pfizer Inc |
β3 -Adrenoceptor agonists and antagonists for the treatment of intestinal motility disorders, depression, prostate disease and dyslipidemia
|
US5731307A
(en)
|
1994-09-30 |
1998-03-24 |
Pfizer, Inc. |
Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines
|
US5516759A
(en)
|
1994-12-08 |
1996-05-14 |
Tap Holdings Inc. |
LHRH antagonists having lactam groups at the N-terminus
|
US5658590A
(en)
|
1995-01-11 |
1997-08-19 |
Eli Lilly And Company |
Treatment of attention-deficit/hyperactivity disorder
|
US5741789A
(en)
|
1995-01-17 |
1998-04-21 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
US5576321A
(en)
|
1995-01-17 |
1996-11-19 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
WO1996024353A1
(en)
|
1995-02-10 |
1996-08-15 |
Eli Lilly And Company |
Methods of treating or preventing psychiatric disorders
|
CR5278A
(es)
|
1995-03-24 |
1996-07-04 |
Lilly Co Eli |
Formulacion oral de 2-metil-tieno-benzodiacepina
|
EG23659A
(en)
|
1995-03-24 |
2007-03-26 |
Lilly Co Eli |
Process and crystal forms of methyl-thieno-benzodiazepine
|
JPH11503757A
(ja)
|
1995-04-18 |
1999-03-30 |
イーライ・リリー・アンド・カンパニー |
5−ht▲下7▼レセプターにおいて生理学的および病理学的機能を生じるエルゴリン化合物の使用方法
|
US5889010A
(en)
|
1995-05-18 |
1999-03-30 |
Pfizer Inc. |
Benzimidazole derivatives having dopaminergic activity
|
US20010023248A1
(en)
|
1995-05-25 |
2001-09-20 |
Howard Harry R. |
Aminomethylene substituted non-aromatic heterocycles and use as substance P antagonists
|
US6403599B1
(en)
|
1995-11-08 |
2002-06-11 |
Pfizer Inc |
Corticotropin releasing factor antagonists
|
IL118279A
(en)
|
1995-06-07 |
2006-10-05 |
Abbott Lab |
Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
|
CA2226292C
(en)
|
1995-07-07 |
2001-12-11 |
Pfizer Inc. |
Substituted benzolactam compounds as substance p antagonists
|
NZ313076A
(en)
|
1995-07-24 |
1999-11-29 |
Lilly Co Eli |
Medicament containing duloxetine for treating hyperactivity and attention deficiency disorders
|
US5696168A
(en)
|
1995-07-24 |
1997-12-09 |
Eli Lilly And Company |
Treatment of attention-deficit/hyperactivity disorder
|
TW340842B
(en)
|
1995-08-24 |
1998-09-21 |
Pfizer |
Substituted benzylaminopiperidine compounds
|
IL115113A
(en)
|
1995-08-31 |
2002-11-10 |
Israel State |
3-carbamoyloxy pyridinium derivatives and pharmaceutical compositions containing them
|
ES2100129B1
(es)
|
1995-10-11 |
1998-02-16 |
Medichem Sa |
Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
|
ATE240942T1
(de)
|
1995-11-17 |
2003-06-15 |
Merck & Co Inc |
Neue substituierte aryl-verbindungen als acetylcholine receptors modulatoren
|
US5783584A
(en)
|
1995-12-11 |
1998-07-21 |
Mayo Foundation For Medical Education And Research |
THA analogs useful as cholinesterase inhibitors
|
EP0780375B1
(en)
|
1995-12-21 |
2002-09-11 |
Pfizer Inc. |
3-((5-substituted benzyl)amino)-2-phenylpiperidines as substance p antagonists
|
WO1997023220A1
(en)
|
1995-12-22 |
1997-07-03 |
Eli Lilly And Company |
Method for treating depression
|
US5625897A
(en)
|
1996-01-11 |
1997-05-06 |
Park; Kelly R. |
Upper torso garment
|
PT874625E
(pt)
|
1996-01-22 |
2005-07-29 |
Lilly Co Eli |
Derivados de indano para composicoes antipsicoticas
|
GB9606736D0
(en)
|
1996-02-19 |
1996-06-05 |
Shire International Licensing |
Therapeutic method
|
BR9612548A
(pt)
|
1996-03-11 |
1999-07-20 |
Lilly Co Eli |
Método para tratar distúrbio bipolar
|
JP2000507544A
(ja)
|
1996-03-25 |
2000-06-20 |
イーライ・リリー・アンド・カンパニー |
痛みの治療方法
|
US6326368B1
(en)
|
1996-03-27 |
2001-12-04 |
Dupont Pharmaceuticals Company |
Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
|
US6107300A
(en)
|
1996-03-27 |
2000-08-22 |
Dupont Pharmaceuticals |
Arylamino fused pyrimidines
|
KR100305071B1
(ko)
|
1996-03-29 |
2001-12-12 |
디. 제이. 우드, 스피겔 알렌 제이 |
벤질-락탐유도체및/또는벤질리덴-락탐유도체,이들의제조방법및이들의세로토닌1에이및/또는세로토닌1디수용체의선택적인길항제및/또는작용제로서의용도
|
NZ500927A
(en)
|
1996-03-29 |
2004-11-26 |
Pfizer |
6-Phenylpyridyl-2-amine derivatives
|
JP4109718B2
(ja)
|
1996-04-12 |
2008-07-02 |
アベンティス・ファーマスーティカルズ・インコーポレイテッド |
アセチルコリンエステラーゼ阻害剤および鎮痛剤としてのイサチン誘導体
|
ATE236902T1
(de)
|
1996-05-07 |
2003-04-15 |
Pfizer |
Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist
|
TW491847B
(en)
|
1996-05-07 |
2002-06-21 |
Pfizer |
Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
|
TW487572B
(en)
|
1996-05-20 |
2002-05-21 |
Janssen Pharmaceutica Nv |
Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
|
ZA973884B
(en)
|
1996-05-23 |
1998-11-06 |
Du Pont Merck Pharma |
Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
|
US5948437A
(en)
|
1996-05-23 |
1999-09-07 |
Zeneca Limited |
Pharmaceutical compositions using thiazepine
|
EP1380298A3
(en)
|
1996-05-23 |
2004-04-07 |
Bristol-Myers Squibb Pharma Company |
Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders, anorexia, inflammation
|
DE69708968T2
(de)
|
1996-05-28 |
2002-04-25 |
Pfizer |
Arylacrylamidderivate als 5HT1 Agoniste oder Antagoniste
|
TW513409B
(en)
|
1996-06-07 |
2002-12-11 |
Eisai Co Ltd |
Polymorphs of donepezil hydrochloride
|
WO1997046526A1
(en)
|
1996-06-07 |
1997-12-11 |
Eisai Co., Ltd. |
Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production
|
US6329396B1
(en)
|
1996-06-10 |
2001-12-11 |
Pfizer Inc. |
Substituted benzylaminopiperidine compounds
|
US5912256A
(en)
|
1996-06-20 |
1999-06-15 |
Eli Lilly And Company |
Compounds having effects on serotonin-related systems
|
CA2180703A1
(en)
|
1996-07-08 |
1998-01-09 |
Paul Marie Victor Gilis |
Fast-dissolving galanthamine hydrobromide tablet
|
US7094782B1
(en)
|
1996-07-24 |
2006-08-22 |
Bristol-Myers Squibb Company |
Azolo triazines and pyrimidines
|
US6191131B1
(en)
|
1997-07-23 |
2001-02-20 |
Dupont Pharmaceuticals Company |
Azolo triazines and pyrimidines
|
KR100548853B1
(ko)
|
1996-07-24 |
2006-02-02 |
브리스톨-마이어스 스퀴브 파마 컴파니 |
아졸로 트리아진 및 피리미딘
|
US6043258A
(en)
|
1996-08-01 |
2000-03-28 |
Eli Lilly And Company |
Method for treating disruptive behavior disorders with xanomeline
|
US6117890A
(en)
|
1996-08-01 |
2000-09-12 |
Eli Lilly And Company |
Method for treating bipolar disorder
|
DK0821955T3
(da)
|
1996-08-01 |
2002-03-18 |
Lilly Co Eli |
Anvendelse af 3-(4-heoxyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridin (xanomelin) til behandling af bipolar lidelse
|
MX9706196A
(es)
|
1996-08-14 |
1998-02-28 |
Pfizer |
Compuestos triciclicos de piperidinilamino como antagonistas de la sustancia p.
|
WO1998007431A1
(en)
|
1996-08-22 |
1998-02-26 |
New York University |
Cholinesterase inhibitors for treatment of parkinson's disease
|
ZA977967B
(en)
|
1996-09-23 |
1999-03-04 |
Lilly Co Eli |
Combination therapy for treatment of psychoses
|
EA001881B1
(ru)
|
1996-09-23 |
2001-10-22 |
Эли Лилли Энд Компани |
Форма d дигидрата оланзапина
|
UA56185C2
(uk)
|
1996-09-30 |
2003-05-15 |
Пфайзер Інк. |
Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
|
US6423708B1
(en)
|
1996-09-30 |
2002-07-23 |
Pfizer Inc |
Aralkyl and aralkylidene heterocyclic lactams and imides
|
IT1285801B1
(it)
|
1996-10-10 |
1998-06-24 |
Sigma Tau Ind Farmaceuti |
Procedimento migliorato per la preparazione dell'acido valproico
|
DE69735891T2
(de)
|
1996-10-30 |
2006-12-14 |
Pfizer Inc. |
Pyridon-kondensierte azabicyclische- oder cytisinderivate, ihre herstellung und verwendung in der suchttherapie
|
AU5716898A
(en)
|
1997-01-08 |
1998-08-03 |
Warner-Lambert Company |
Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
|
SK283679B6
(sk)
|
1997-01-29 |
2003-11-04 |
Pfizer Inc. |
Deriváty sulfonylmočoviny
|
US6020335A
(en)
|
1997-02-06 |
2000-02-01 |
Pfizer Inc |
(N-(pyridinylmethyl)-heterocyclic)ylideneamine compounds as nicotinic acetylcholine receptor binding agents
|
CA2282654C
(en)
|
1997-03-03 |
2009-02-03 |
Eisai Co., Ltd. |
Use of cholinesterase inhibitors to treat attention deficit hyperactivity disorder
|
GB2323788B
(en)
|
1997-04-02 |
1999-02-17 |
Bristol Myers Squibb Co |
Venting valve for ostomy bag
|
BR9810733A
(pt)
|
1997-04-04 |
2000-09-12 |
Pfizer Prod Inc |
Derivados de nicotinamida
|
ZA982877B
(en)
|
1997-04-09 |
1999-10-04 |
Lilly Co Eli |
Treatment of central nervous system disorders with selective estrogen receptor modulators.
|
AU7107998A
(en)
|
1997-04-11 |
1998-11-11 |
Eli Lilly And Company |
Method for treating schizophrenia
|
AU6896098A
(en)
|
1997-04-11 |
1998-11-11 |
Eli Lilly And Company |
Method for treating schizophrenia
|
US5910319A
(en)
|
1997-05-29 |
1999-06-08 |
Eli Lilly And Company |
Fluoxetine enteric pellets and methods for their preparation and use
|
ATE303997T1
(de)
|
1997-06-09 |
2005-09-15 |
Pfizer Prod Inc |
Chinazolin-4-on ampa antagonisten
|
US6627755B1
(en)
|
1997-06-09 |
2003-09-30 |
Pfizer Inc |
Quinazolin-4-one AMPA antagonists
|
US6060479A
(en)
|
1997-06-09 |
2000-05-09 |
Pfizer Inc |
Quinazoline-4-one AMPA antagonists
|
CA2297906A1
(en)
|
1997-07-22 |
1999-02-04 |
Bret Eugene Huff |
Pharmaceutical compounds
|
GB9716879D0
(en)
|
1997-08-08 |
1997-10-15 |
Shire Int Licensing Bv |
Treatment of attention deficit disorders
|
AU8742198A
(en)
|
1997-08-15 |
1999-03-08 |
Shire International Licensing B.V. |
Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity
|
US6479523B1
(en)
|
1997-08-26 |
2002-11-12 |
Emory University |
Pharmacologic drug combination in vagal-induced asystole
|
IL125951A
(en)
|
1997-09-05 |
2003-09-17 |
Pfizer Prod Inc |
A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
|
US6323208B1
(en)
|
1997-09-05 |
2001-11-27 |
Pfizer Inc |
Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
|
AU9214498A
(en)
|
1997-09-23 |
1999-04-12 |
Eli Lilly And Company |
Treatment of attention-deficit/hyperactivity disorder
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
ATE260896T1
(de)
|
1997-12-05 |
2004-03-15 |
Eisai Co Ltd |
Donepezil polykristalle und verfharen zu ihrer herstellung
|
IL135315A0
(en)
|
1997-12-16 |
2001-05-20 |
Warner Lambert Co |
4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
|
IL127497A
(en)
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
ATE264860T1
(de)
|
1998-01-28 |
2004-05-15 |
Bristol Myers Squibb Pharma Co |
Pyrazolotriazine als crf antagonisten
|
US6131106A
(en)
|
1998-01-30 |
2000-10-10 |
Sun Microsystems Inc |
System and method for floating-point computation for numbers in delimited floating point representation
|
US20020026043A1
(en)
|
1998-02-06 |
2002-02-28 |
Brian Taylor Edmonds |
Desert hedgehog related nucleic acids and proteins
|
GB9805561D0
(en)
|
1998-03-16 |
1998-05-13 |
Merck Sharp & Dohme |
A combination of therapeutic agents
|
PA8469101A1
(es)
|
1998-04-09 |
2000-09-29 |
Pfizer Prod Inc |
Ligandos azabiciclicos de receptores 5ht1
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
PT957099E
(pt)
|
1998-04-15 |
2003-02-28 |
Pfizer Prod Inc |
Carboxamidas heterociclicas
|
ES2226284T3
(es)
|
1998-04-16 |
2005-03-16 |
Pfizer Products Inc. |
N-acil y n-aroil-aralquilamidas.
|
CA2332253A1
(en)
|
1998-05-21 |
1999-11-25 |
Eli Lilly And Company |
Combination therapy for treatment of depression
|
JP2002516282A
(ja)
|
1998-05-22 |
2002-06-04 |
イーライ・リリー・アンド・カンパニー |
難治性鬱病の処置のための組合せ治療
|
GT199900060A
(es)
|
1998-05-22 |
2000-10-14 |
|
Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
|
US6960577B2
(en)
|
1998-05-22 |
2005-11-01 |
Eli Lilly And Company |
Combination therapy for treatment of refractory depression
|
EA003611B1
(ru)
|
1998-05-29 |
2003-06-26 |
Эли Лилли Энд Компани |
Комбинационная терапия для лечения биполярных расстройств
|
US6150366A
(en)
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
US6436914B1
(en)
|
1998-06-30 |
2002-08-20 |
Bristol-Myers Squibb Company |
2-hydroxy-3—(4-hydroxy-3-sulfonamidophenyl)—propylamines useful as beta 3 adrenergic agonists
|
US6312717B1
(en)
|
1998-07-07 |
2001-11-06 |
Bristol-Myers Squibb Company |
Method for treatment of anxiety and depression
|
US6262081B1
(en)
|
1998-07-10 |
2001-07-17 |
Dupont Pharmaceuticals Company |
Composition for and method of treating neurological disorders
|
US6218383B1
(en)
|
1998-08-07 |
2001-04-17 |
Targacept, Inc. |
Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
|
EE200100085A
(et)
|
1998-08-11 |
2002-08-15 |
Pfizer Products Inc. |
Asendatud 1,8-naftüridiin-4(1H)-oonid kui fosfodiesteraas 4 inhibiitorid
|
IL125809A
(en)
|
1998-08-17 |
2005-08-31 |
Finetech Lab Ltd |
Process and intermediates for production of donepezil and related compounds
|
IT1304904B1
(it)
|
1998-09-11 |
2001-04-05 |
Eisai Co Ltd |
Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche
|
HN1999000146A
(es)
|
1998-09-21 |
2000-11-11 |
Pfizer Prod Inc |
Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
|
KR20010072878A
(ko)
|
1998-10-16 |
2001-07-31 |
디르크 반테 |
인식을 개선하기 위한 아세틸콜린에스테라제 억제제와배합된 비정형 항정신병제
|
US5994352A
(en)
|
1998-11-13 |
1999-11-30 |
Pfizer Inc. |
5-arylindole derivatives
|
AU1738800A
(en)
|
1998-11-23 |
2000-06-13 |
Bonnie Davis |
Dosage formulations for acetylcholinesterase inhibitors
|
US6627771B1
(en)
|
1998-11-25 |
2003-09-30 |
Pfizer Inc |
Gamma amino butyric and acid analogs
|
AU2354400A
(en)
|
1998-12-11 |
2000-06-26 |
Bonnie Davis |
Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis
|
UA62015C2
(en)
|
1998-12-28 |
2003-12-15 |
Pfizer Prod Inc |
Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants)
|
US6271380B1
(en)
|
1998-12-30 |
2001-08-07 |
Dupont Pharmaceuticals Company |
1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
|
AU2180400A
(en)
|
1999-01-13 |
2000-08-01 |
Eli Lilly And Company |
A pharmaceutical combination for the treatment of depression
|
CA2363145C
(en)
|
1999-03-01 |
2006-02-14 |
Pfizer Products Inc. |
Oxamic acids and derivatives as thyroid receptor ligands
|
ATE289586T1
(de)
|
1999-03-01 |
2005-03-15 |
Pfizer Prod Inc |
Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
|
US6277866B1
(en)
|
1999-03-03 |
2001-08-21 |
Eisai Co., Ltd. |
1-benzyl-4[(5,6-dimethoxy-2-fluoro-1-indanon)-2-yl]methylpiperidine
|
PT1086706E
(pt)
|
1999-03-31 |
2004-02-27 |
Eisai Co Ltd |
Composicao estabilizada que compreende um medicamento nootropico
|
EP1050303A3
(en)
|
1999-04-27 |
2003-01-15 |
Pfizer Products Inc. |
Methods and compositions for treating age-related behavioral disorders in companion animals
|
JP2003523941A
(ja)
|
1999-05-21 |
2003-08-12 |
ファイザー・プロダクツ・インク |
Nos阻害剤のための新規医薬組合せ
|
AU4973800A
(en)
|
1999-06-09 |
2000-12-28 |
Eli Lilly And Company |
Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
|
ES2228549T3
(es)
|
1999-06-15 |
2005-04-16 |
Bristol-Myers Squibb Pharma Company |
Gamma-carbolinas condensadas con heterociclo sustituido.
|
US6713471B1
(en)
|
1999-06-15 |
2004-03-30 |
Bristol-Myers Squibb Pharma Company |
Substituted heterocycle fused gamma-carbolines
|
US6524616B1
(en)
|
1999-06-25 |
2003-02-25 |
Wake Forest University Health Services |
Compositions and methods for treating or preventing neurodegeneration and cognitive decline and dysfunction associated with alzheimer's disease, aging, other dementia related disorders and estrogen deficiency related conditions
|
US6432989B1
(en)
|
1999-08-27 |
2002-08-13 |
Pfizer Inc |
Use of CRF antagonists to treat circadian rhythm disorders
|
WO2001016105A1
(fr)
|
1999-09-01 |
2001-03-08 |
Eisai Co., Ltd. |
Derives de piperidine 4-substituee
|
JP4242048B2
(ja)
|
1999-09-01 |
2009-03-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
4−置換ピペリジン誘導体
|
CN1167682C
(zh)
|
1999-09-22 |
2004-09-22 |
先灵公司 |
毒蕈碱拮抗剂
|
DK1088819T3
(da)
|
1999-09-30 |
2005-09-12 |
Pfizer Prod Inc |
6-azauracilderivater som thyroidreceptorligander
|
CA2324813A1
(en)
|
1999-11-10 |
2001-05-10 |
Susan Beth Sobolov-Jaynes |
Combination treatment for depression and anxiety
|
US6620802B1
(en)
|
1999-11-23 |
2003-09-16 |
Corcept Therapeutics, Inc. |
Methods of treating mild cognitive impairment using a glucocorticoid-specific receptor antagonist
|
HUP0204023A3
(en)
*
|
1999-12-01 |
2005-03-29 |
Ucb Sa |
A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders and pharmaceutical compositions containing them
|
JP2003516992A
(ja)
|
1999-12-17 |
2003-05-20 |
デュポン ファーマシューティカルズ カンパニー |
イミダゾピリミジニル誘導体およびイミダゾピリジニル誘導体
|
CA2394548A1
(en)
|
1999-12-17 |
2001-06-21 |
Joseph P. Yevich |
Antipsychotic heterocycle compounds
|
US6844344B2
(en)
|
1999-12-20 |
2005-01-18 |
Eli Lilly And Company |
Benzofuran derivatives
|
AU1930901A
(en)
|
1999-12-20 |
2001-07-03 |
Eli Lilly And Company |
Azabicyclo(3.2.1)octane derivatives
|
US7144898B2
(en)
|
1999-12-20 |
2006-12-05 |
Eli Lilly And Company |
Indole derivatives for the treatment of depression and anxiety
|
US6835733B2
(en)
|
1999-12-20 |
2004-12-28 |
Eli Lilly And Company |
Tropane linked benzofuran derivatives
|
EP1250336B1
(en)
|
1999-12-20 |
2004-05-12 |
Eli Lilly And Company |
Piperidine derivatives and their use as serotonin receptor antagonists
|
EP1113015B1
(en)
|
1999-12-29 |
2004-09-15 |
Pfizer Products Inc. |
Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists
|
EP1127882A1
(en)
|
2000-01-25 |
2001-08-29 |
Pfizer Products Inc. |
Tetrazole compounds as thyroid receptor ligands
|
MXPA02007929A
(es)
|
2000-02-17 |
2003-02-10 |
Squibb Bristol Myers Co |
Ligandos derivados de anilina para el receptor de la tiroides.
|
GB0004297D0
(en)
|
2000-02-23 |
2000-04-12 |
Ucb Sa |
2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
|
DK1311272T3
(da)
|
2000-03-03 |
2007-02-26 |
Eisai R&D Man Co Ltd |
Hidtil ukendte fremgangsmåder hvor der anvendes cholinesteraseinhibitorer
|
US20030144255A1
(en)
|
2000-03-06 |
2003-07-31 |
Bain Allen I |
Compositions for prevention and treatment of dementia
|
EP1265857A1
(en)
|
2000-03-13 |
2002-12-18 |
Eli Lilly And Company |
Sulfonamide derivatives
|
GB0007884D0
(en)
|
2000-03-31 |
2000-05-17 |
Pfizer Ltd |
Diphenyl ether compounds useful in therapy
|
US6664291B2
(en)
|
2000-03-31 |
2003-12-16 |
Pfizer, Inc. |
Malonamic acids and derivatives thereof as thyroid receptor ligands
|
IL151376A0
(en)
|
2000-03-31 |
2003-04-10 |
Pfizer Prod Inc |
Malonamic acids and derivatives thereof as thyroid receptor ligands
|
ATE350378T1
(de)
|
2000-04-08 |
2007-01-15 |
Boehringer Ingelheim Pharma |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
EA005409B1
(ru)
|
2000-04-10 |
2005-02-24 |
Пфайзер Продактс Инк. |
Производные бензамидопиперидина в качестве антагонистов рецепторов вещества p
|
US6706741B2
(en)
|
2000-04-13 |
2004-03-16 |
Eisai Co., Ltd. |
Acetylcholinesterase inhibitors containing 1-benzyl-pyridinium salts
|
US6620830B2
(en)
|
2000-04-21 |
2003-09-16 |
Pfizer, Inc. |
Thyroid receptor ligands
|
US6630469B2
(en)
|
2000-05-09 |
2003-10-07 |
Bristol-Myers Squibb Company |
5-HT7 receptor antagonists
|
US20010036949A1
(en)
|
2000-05-09 |
2001-11-01 |
Coe Jotham Wadsworth |
Pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal
|
US20040229911A1
(en)
|
2000-05-17 |
2004-11-18 |
Pfizer Inc |
New pharmaceutical combinations for NOS inhibitors
|
AU2001261022A1
(en)
|
2000-05-24 |
2001-12-03 |
Eli Lilly And Company |
Combination therapy for treatment of depression comprising an antidepressant and an ampa receptor potentiator
|
IL152202A0
(en)
|
2000-05-26 |
2003-05-29 |
Bristol Myers Squibb Co |
Human kcnq5 polypeptide and pharmaceutical compositions containing the same
|
PT1468686E
(pt)
|
2000-06-02 |
2007-01-31 |
Pfizer Prod Inc |
S-metil-di-hidro-ziprasidona para o tratamento de distúrbios psiquiátricos
|
US6395784B1
(en)
|
2000-06-07 |
2002-05-28 |
Bristol-Myers Squibb Company |
Benzamide ligands for the thyroid receptor
|
DOP2001000189A
(es)
|
2000-06-30 |
2002-03-30 |
Pfizer Prod Inc |
Benzofenonas y sulfonas como inhibidores de la captación de glicina
|
EP1316203A2
(en)
|
2000-06-30 |
2003-06-04 |
Eli Lilly And Company |
Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
|
US6630476B2
(en)
|
2000-07-07 |
2003-10-07 |
Bristol-Myers Squibb Pharma Company |
Pyrrolo [3,4-d] pyrimidines as corticotropin releasing factor (CRF) antagonists
|
EP1177792A3
(en)
|
2000-07-27 |
2002-10-23 |
Pfizer Products Inc. |
Dopamine D4 Ligands for the treatment of novelty-seeking disorders
|
US6756385B2
(en)
|
2000-07-31 |
2004-06-29 |
Pfizer Inc. |
Imidazole derivatives
|
US20020016334A1
(en)
|
2000-07-31 |
2002-02-07 |
Coe Jotham Wadsworth |
Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD)
|
US20020049211A1
(en)
|
2000-09-06 |
2002-04-25 |
Sobolov-Jaynes Susan Beth |
Combination treatment for depression and anxiety
|
AU2001282913A1
(en)
|
2000-09-08 |
2002-03-22 |
Eli Lilly And Company |
A method of treating weight gain associated with atypical antipsychotic use
|
EP1320365A4
(en)
|
2000-09-21 |
2004-03-17 |
Bristol Myers Squibb Co |
SUBSTITUTED AZOLE DERIVATIVES AS AN INHIBITOR OF THE CORTICOTROPIN RELEASE FACTOR
|
EP1192952A3
(en)
|
2000-09-28 |
2003-03-26 |
Pfizer Products Inc. |
Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
|
IL145584A0
(en)
|
2000-10-02 |
2002-06-30 |
Pfizer Prod Inc |
Nmda nr2b antagonists for treatment
|
US20020151591A1
(en)
|
2000-10-17 |
2002-10-17 |
Anabella Villalobos |
Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
|
US20020103198A1
(en)
|
2000-12-04 |
2002-08-01 |
Fliri Anton F.J |
Acylamino cyclopropane derivatives
|
CA2364211A1
(en)
|
2000-12-05 |
2002-06-05 |
Phillip Branch Chappell |
Combination treatment for depression, anxiety and psychosis
|
UA73619C2
(en)
|
2000-12-13 |
2005-08-15 |
Pfizer Prod Inc |
Stable pharmaceutical compositions of nmda receptor agonist (variants) and method of treatment
|
EE200300301A
(et)
|
2000-12-20 |
2003-10-15 |
Bristol-Myers Squibb Pharma Company |
Asendatud pürasinokinoksaliini derivaadid kui serotoniiniretseptorite agonistid ja antagonistid
|
WO2002059129A2
(en)
|
2000-12-20 |
2002-08-01 |
Bristol-Myers Squibb Company |
Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists
|
HUP0303530A3
(en)
|
2000-12-20 |
2012-10-29 |
Bristol Myers Squibb Co |
Stituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists and pharmaceutical compositions containing them
|
US6849619B2
(en)
|
2000-12-20 |
2005-02-01 |
Bristol-Myers Squibb Company |
Substituted pyridoindoles as serotonin agonists and antagonists
|
MXPA03005889A
(es)
|
2000-12-28 |
2005-02-14 |
Daiichi Seiyaku Co |
Agente para tratamiento terapeutico y profilactico del dolor neuropatico.
|
US20020086871A1
(en)
|
2000-12-29 |
2002-07-04 |
O'neill Brian Thomas |
Pharmaceutical composition for the treatment of CNS and other disorders
|
US6436938B1
(en)
|
2001-01-22 |
2002-08-20 |
Pfizer Inc. |
Combination treatment for depression
|
US6888004B2
(en)
|
2001-01-26 |
2005-05-03 |
Bristol-Myers Squibb Company |
Imidazolyl derivatives as corticotropin releasing factor inhibitors
|
US20020107244A1
(en)
|
2001-02-02 |
2002-08-08 |
Howard Harry R. |
Combination treatment for depression
|
US6610326B2
(en)
|
2001-02-16 |
2003-08-26 |
Andrx Corporation |
Divalproex sodium tablets
|
US20040116505A1
(en)
|
2001-02-23 |
2004-06-17 |
Gregory Krauss |
Treatment of tics, tremors and related disorders
|
US20020123490A1
(en)
|
2001-03-01 |
2002-09-05 |
Pfizer Inc. |
Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
|
WO2002072101A1
(en)
|
2001-03-13 |
2002-09-19 |
Bristol-Myers Squibb Pharma Company |
A corticotropin releasing factor receptor ligand, its enantiomer and pharmaceutically acceptable salts
|
DK1368094T3
(da)
|
2001-03-13 |
2007-07-02 |
Bristol Myers Squibb Pharma Co |
4-(2-Butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl)-pyrazolo[1,5-a]-1,3,5-triazin, dens enantiomerer og farmaceutisk acceptable salte som corticotropin-frigivende faktor-receptor- ligander
|
CA2442717A1
(en)
|
2001-03-15 |
2002-09-26 |
Saegis Pharmaceuticals, Inc. |
Methods for restoring cognitive function following systemic stress
|
ATE372768T1
(de)
|
2001-03-29 |
2007-09-15 |
Lilly Co Eli |
N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
|
MXPA03008807A
(es)
|
2001-03-29 |
2004-02-12 |
Bristol Myers Squibb Co |
Derivados de ciclopropilindol como inhibidores selectivos de recaptacion de serotonina.
|
SK12822003A3
(sk)
|
2001-04-19 |
2004-04-06 |
Warner - Lambert Company Llc |
Fúzne bicyklické alebo tricyklické aminokyseliny
|
US20030018047A1
(en)
|
2001-04-20 |
2003-01-23 |
Pfizer Inc. |
Therapeutic use of selective PDE10 inhibitors
|
US20030032579A1
(en)
|
2001-04-20 |
2003-02-13 |
Pfizer Inc. |
Therapeutic use of selective PDE10 inhibitors
|
IL149106A0
(en)
|
2001-04-20 |
2002-11-10 |
Pfizer Prod Inc |
Therapeutic use of selective pde10 inhibitors
|
EP1666886A3
(en)
|
2001-04-20 |
2006-06-21 |
Pfizer Products Inc. |
Method of identifying selective PDE10 inhibitor compounds
|
MY129350A
(en)
|
2001-04-25 |
2007-03-30 |
Bristol Myers Squibb Co |
Aripiprazole oral solution
|
AU2756602A
(en)
|
2001-04-25 |
2002-10-31 |
Pfizer Products Inc. |
Methods and kits for treating depression or preventing deterioration of cognitive function
|
US20020165217A1
(en)
|
2001-05-01 |
2002-11-07 |
Pfizer Inc. |
Combination treatment for anxiety and depression
|
ATE315555T1
(de)
|
2001-05-11 |
2006-02-15 |
Pfizer Prod Inc |
Thiazolderivate und ihre verwendung als cdk- inhibitoren
|
EP1392309B1
(en)
|
2001-05-14 |
2007-01-17 |
Bristol-Myers Squibb Company |
Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
|
WO2002094787A1
(en)
|
2001-05-23 |
2002-11-28 |
Ucb, S.A. |
2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
|
EP1260221A3
(en)
|
2001-05-23 |
2002-12-18 |
Pfizer Products Inc. |
Combination treatment for depression and anxiety
|
US6566550B2
(en)
|
2001-06-21 |
2003-05-20 |
Pfizer Inc |
Substituted aromatic ethers as inhibitors of glycine transport
|
US20030008892A1
(en)
|
2001-07-09 |
2003-01-09 |
Pfizer Inc. |
Pharmaceutical composition and method of modulating cholinergic function in a mammal
|
US6894045B2
(en)
|
2001-07-12 |
2005-05-17 |
Bristol-Myers Squibb Pharma Company |
Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
|
US7276526B2
(en)
|
2001-07-13 |
2007-10-02 |
Bristol-Myers Squibb Pharma Company |
Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
|
WO2003009851A1
(en)
|
2001-07-24 |
2003-02-06 |
Bristol-Myers Squibb Company |
R-6-hydroxy-buspirone
|
WO2003010161A1
(en)
|
2001-07-24 |
2003-02-06 |
Bristol-Myers Squibb Company |
S-6-hydroxy-buspirone
|
US8354438B2
(en)
|
2001-08-08 |
2013-01-15 |
Michael Chez |
Neurological functions
|
DE60206454T2
(de)
|
2001-08-16 |
2006-06-29 |
Pfizer Products Inc., Groton |
Difluormethylen aromatische Ether und ihre Verwendung als Inhibitoren des Glycin-Typ-1-Transporters
|
ATE404192T1
(de)
|
2001-08-22 |
2008-08-15 |
Hamilton Pharmaceuticals Inc |
Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
|
EP1423127A1
(en)
|
2001-08-30 |
2004-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Treatment of dementia and memory disorders with anticonvulsants and acetylcholinesterase inhibitors
|
US7297708B2
(en)
|
2001-09-06 |
2007-11-20 |
Bristol-Myers Squibb Company |
Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
|
EP1297833B1
(en)
|
2001-09-26 |
2005-12-21 |
Pfizer Products Inc. |
Indole carboxylic acids as thyroid receptor ligands
|
US20040235957A1
(en)
|
2001-10-12 |
2004-11-25 |
David Bleakman |
Use of sulfonamide derivatives as pharmaceuticals compounds
|
EP1435944B1
(en)
|
2001-10-16 |
2009-09-30 |
Memory Pharmaceutical Corporation |
4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
|
KR20010113584A
(ko)
|
2001-11-08 |
2001-12-28 |
(주)시스튜디오 |
컴퓨터에 의한 만화 애니메이션 구현방법 및 만화애니메이션 실행데이터를 기록한 컴퓨터로 읽을 수 있는기록매체
|
US6673811B1
(en)
|
2001-11-19 |
2004-01-06 |
Neurogen Corporation |
1H-pyrrolo [3,2-b] pyridine-3-carboxylic acid amines as GABAA receptor ligands
|
WO2003043637A1
(en)
|
2001-11-20 |
2003-05-30 |
Bristol-Myers Squibb Pharma Company |
3,7-dihydro-purine-2,6-dione derivatives as crf receptor ligands
|
US6992087B2
(en)
|
2001-11-21 |
2006-01-31 |
Pfizer Inc |
Substituted aryl 1,4-pyrazine derivatives
|
MXPA02010430A
(es)
|
2001-11-27 |
2003-06-02 |
Warner Lambert Co |
Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas.
|
DE60223718T2
(de)
|
2001-12-11 |
2008-10-30 |
Eli Lilly And Co., Indianapolis |
Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
|
US6495700B1
(en)
|
2002-01-09 |
2002-12-17 |
Axonyx, Inc. |
Process for producing phenserine and its analog
|
US20050009927A1
(en)
|
2002-01-23 |
2005-01-13 |
Pfizer Inc |
Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
|
US20050014848A1
(en)
|
2002-01-23 |
2005-01-20 |
Pfizer Inc. |
Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
|
EP1476165A1
(en)
|
2002-02-22 |
2004-11-17 |
PHARMACIA & UPJOHN COMPANY |
Substituted pyrimidinones and pyrimidinthiones
|
US20040167200A1
(en)
|
2002-03-25 |
2004-08-26 |
Pfizer Inc. |
Pharmaceutical composition and method of modulating cholinergic function in a mammal
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
CA2479932A1
(en)
|
2002-03-28 |
2003-10-09 |
Eli Lilly And Company |
Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
|
US6759552B2
(en)
|
2002-03-28 |
2004-07-06 |
Council Of Scientific And Industrial Research |
Compound as cholinesterase inhibitor and its isolation from fungus sporotrichum species
|
EP1491531B1
(en)
|
2002-03-29 |
2007-12-26 |
Eisai R&D Management Co., Ltd. |
(1-indanone)-(1,2,3,6-tetrahydropyridine) derivative
|
AU2003218063A1
(en)
|
2002-04-03 |
2003-10-20 |
Eli Lilly And Company |
Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
|
WO2003091220A1
(en)
|
2002-04-26 |
2003-11-06 |
Schering Corporation |
Muscarinic antagonists
|
US6713490B2
(en)
|
2002-04-26 |
2004-03-30 |
Pfizer, Inc. |
3,4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists
|
AU2003298514A1
(en)
|
2002-05-17 |
2004-05-04 |
Eisai Co., Ltd. |
Methods and compositions using cholinesterase inhibitors
|
MXPA04011762A
(es)
|
2002-05-31 |
2005-03-31 |
Lundbeck & Co As H |
Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer.
|
US6710040B1
(en)
|
2002-06-04 |
2004-03-23 |
Pfizer Inc. |
Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
|
US20030235631A1
(en)
|
2002-06-17 |
2003-12-25 |
Pfizer Inc. |
Combination treatment for depression and anxiety
|
US20040001895A1
(en)
|
2002-06-17 |
2004-01-01 |
Pfizer Inc. |
Combination treatment for depression and anxiety
|
US20040006135A1
(en)
|
2002-06-19 |
2004-01-08 |
Pfizer Inc. |
Combination treatment for depression and anxiety
|
US20040116506A1
(en)
|
2002-06-20 |
2004-06-17 |
Krusz John Claude |
Use of levetiracetam for treating or preventing acute headaches
|
US6875771B2
(en)
|
2002-07-26 |
2005-04-05 |
Bristol-Myers Squibb Company |
Pyridopyrimidine derivatives as 5-HT6 antagonists
|
ATE361289T1
(de)
|
2002-08-05 |
2007-05-15 |
Lilly Co Eli |
Piperazinsubstituierte arylbenzodiazepine
|
US7557137B2
(en)
|
2002-08-05 |
2009-07-07 |
Bristol-Myers Squibb Company |
Gamma-lactams as beta-secretase inhibitors
|
US7053122B2
(en)
|
2002-08-09 |
2006-05-30 |
Pfizer Inc |
Therapeutic use of aryl amino acid derivatives
|
GB0219154D0
(en)
|
2002-08-16 |
2002-09-25 |
Pfizer Ltd |
Diaryl compounds
|
GB0219153D0
(en)
|
2002-08-16 |
2002-09-25 |
Pfizer Ltd |
Substituted glycine derivatives for use as medicaments
|
ES2322953T3
(es)
|
2002-08-20 |
2009-07-02 |
Bristol-Myers Squibb Company |
Formulacion del complejo de aripiprazol y procedimiento.
|
JP2006504690A
(ja)
|
2002-09-10 |
2006-02-09 |
ファイザー・プロダクツ・インク |
Cns及びその他の障害の治療に有用なジアザ二環式化合物
|
TW200418838A
(en)
|
2002-09-18 |
2004-10-01 |
Bristol Myers Squibb Co |
Compounds for the treatment of premature ejaculation
|
US7049314B2
(en)
|
2002-09-18 |
2006-05-23 |
Bristol-Myers Squibb Company |
Cyclopentyl indole derivatives
|
US7635709B2
(en)
|
2002-09-26 |
2009-12-22 |
The United States Of America As Represented By The Department Of Veterans Affairs |
Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
|
US7067658B2
(en)
|
2002-09-30 |
2006-06-27 |
Bristol-Myers Squibb Company |
Pyridino and pyrimidino pyrazinones
|
GB0223494D0
(en)
|
2002-10-09 |
2002-11-13 |
Neuropharma Sa |
Dual binding site acetylcholinesterase inhibitors for the treatment of alzheimer's disease
|
PL376476A1
(en)
|
2002-10-24 |
2005-12-27 |
Merz Pharma Gmbh & Co.Kgaa |
Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
|
BR0315516A
(pt)
|
2002-10-24 |
2005-08-23 |
Pfizer Prod Inc |
Derivados de acila de 5-(2-(4-(1,2-benzoisotiazol-3-il)-1-piperazinil)etil)-6-clo ro-1,3-dihidro-2h-indol-2-ona tendo atividade neuroléptica
|
GB0225379D0
(en)
|
2002-10-31 |
2002-12-11 |
Pfizer Ltd |
Therapeutic proline derivatives
|
BR0316327A
(pt)
|
2002-11-18 |
2005-09-27 |
Pfizer Prod Inc |
Amidas cìclicas fluorinadas inibidoras de dipeptidilpeptidase iv
|
EP1572112A4
(en)
|
2002-11-22 |
2006-12-06 |
Bristol Myers Squibb Co |
3- (PYRIDINYL-PIPERAZINE-1-YL) -PHENYLETHYL AMIDES AS POTASIC CHANNEL OPENING AGENTS
|
WO2004047738A2
(en)
|
2002-11-22 |
2004-06-10 |
Bristol-Myers Squibb Company |
Arylcyclopropylcarboxylic amides as potassium channel openers
|
WO2004047744A2
(en)
|
2002-11-22 |
2004-06-10 |
Bristol-Myers Squibb Company |
3-heterocyclic benzylamide derivatives as potassium channel openers
|
AU2003294441A1
(en)
|
2002-11-22 |
2004-06-18 |
Bristol-Myers Squibb Company |
1-aryl-2-hydroxyethyl amides as potassium channel openers
|
AU2003295782A1
(en)
|
2002-11-22 |
2004-06-18 |
Bristol-Myers Squibb Company |
Pyridinyl, pyrimidinyl and pyrazinyl amides as potassium channel openers
|
EP1897959A1
(en)
|
2002-11-22 |
2008-03-12 |
The Johns Hopkins University |
Target for therapy of cognitive impairment
|
JP2006516390A
(ja)
|
2002-12-03 |
2006-07-06 |
ユ セ ベ ソシエテ アノニム |
発作、神経系疾患、内分泌障害及びホルモン疾患の治療用薬剤の同定方法
|
US7090985B2
(en)
|
2002-12-03 |
2006-08-15 |
Ucb, S.A. |
Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases
|
EP1572205A2
(en)
|
2002-12-11 |
2005-09-14 |
Pharmacia & Upjohn Company LLC |
Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds
|
AU2003283656A1
(en)
|
2002-12-11 |
2004-06-30 |
Pharmacia & Upjohn Company Llc |
Combination for the treatment of adhd
|
CA2514656A1
(en)
|
2003-01-31 |
2004-08-12 |
Pfizer Products Inc. |
5ht7 antagonists and inverse agonists
|
ZA200507322B
(en)
|
2003-03-06 |
2007-03-28 |
Celgene Corp |
Selective cytokine inhibitory drugs for treating disorders of the central nervous system
|
UA78437C2
(en)
|
2003-03-12 |
2007-03-15 |
Pfizer Prod Inc |
Azabicyclic derivatives of pyridyloxymethyl and benzisoxazole
|
ITMI20030573A1
(it)
|
2003-03-24 |
2004-09-25 |
Nikem Research Srl |
Composti ad azione nootropica, loro preparazione,
|
US20040191334A1
(en)
|
2003-03-24 |
2004-09-30 |
Pang-Chui Shaw |
Use of transhinone derivates as cholinesterase inhibitors in treating related diseases
|
CA2520251A1
(en)
|
2003-03-27 |
2004-10-07 |
Pfizer Products Inc. |
Substituted 4-amino[1,2,4]triazolo[4,3-a]quinoxalines
|
TW200508197A
(en)
|
2003-03-31 |
2005-03-01 |
Ucb Sa |
Indolone-acetamide derivatives, processes for preparing them and their uses
|
US7041671B2
(en)
|
2003-04-02 |
2006-05-09 |
Pfizer Inc |
Pyrrolo[1,2-b]pyridazine compounds and their uses
|
US7056920B2
(en)
|
2003-04-04 |
2006-06-06 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
US7034023B2
(en)
|
2003-04-04 |
2006-04-25 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
US7056930B2
(en)
|
2003-04-14 |
2006-06-06 |
Pfizer Inc. |
2-Azabicyclo[3.3.1]nonane derivatives
|
US20040204453A1
(en)
|
2003-04-14 |
2004-10-14 |
Pfizer Inc |
4-Phenyl-piperidine compounds and their use as modulators of opioid receptors
|
CA2522323C
(en)
|
2003-04-14 |
2009-09-15 |
Pfizer Products Inc. |
3-azabicyclo[3.2.1]octane derivatives as opioid receptor ligands
|
US7112585B2
(en)
|
2003-04-18 |
2006-09-26 |
Bristol-Myers Squibb Company |
Pyrimidine derivatives as corticotropin releasing factor inhibitors
|
US7030145B2
(en)
|
2003-04-18 |
2006-04-18 |
Bristol-Myers Squibb Company |
Pyridinyl derivatives for the treatment of depression
|
BRPI0409649A
(pt)
|
2003-04-23 |
2006-04-25 |
Pharmacia & Upjohn Co Llc |
pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
|
GB0309440D0
(en)
|
2003-04-25 |
2003-06-04 |
Lilly Co Eli |
Quinolone derivatives
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
WO2004099213A2
(en)
|
2003-05-07 |
2004-11-18 |
Pharmacia & Upjohn Company Llc |
Pyrrolo (1,2-b) pyridazine compounds and their use as crf-1 receptor antagonists
|
JP2006525987A
(ja)
|
2003-05-09 |
2006-11-16 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
置換ピリミジン誘導体
|
WO2004100992A2
(en)
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
MXPA05012391A
(es)
|
2003-05-16 |
2006-02-02 |
Pfizer Prod Inc |
Tratamiento de trastornos psicoticos y depresivos.
|
KR20060009938A
(ko)
|
2003-05-16 |
2006-02-01 |
화이자 프로덕츠 인코포레이티드 |
양극성 장애 및 연관된 증상의 치료
|
MXPA05012325A
(es)
|
2003-05-16 |
2006-01-30 |
Pfizer Prod Inc |
Procedimiento para potenciar la cognicion usando zipirasidona.
|
AU2004243096B2
(en)
|
2003-05-23 |
2008-12-18 |
Otsuka Pharmaceutical Co., Ltd. |
Carbostyril derivatives and mood stabilizers for treating mood disorders
|
US7101881B2
(en)
|
2003-06-11 |
2006-09-05 |
Pfizer Inc |
Tetrahydroquinolines
|
EP1638932A1
(en)
|
2003-06-18 |
2006-03-29 |
Pfizer Products Inc. |
Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams
|
DE602004015603D1
(de)
|
2003-06-27 |
2008-09-18 |
Pfizer Prod Inc |
Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
|
WO2005000303A1
(en)
|
2003-06-27 |
2005-01-06 |
Pfizer Products Inc. |
Pyrazolo`3,4-b!pyridin-6-ones as gsk-3 inhibitors
|
US20050070577A1
(en)
|
2003-07-03 |
2005-03-31 |
Pfizer Inc. |
Compositions containing a serotonin selective reuptake inhibitor and a 5-HT2A receptor antagonist
|
WO2005013961A1
(en)
|
2003-07-17 |
2005-02-17 |
Eli Lilly And Company |
Combination therapy for treatment of cognitive disorders or psychoses
|
TW200510324A
(en)
|
2003-08-11 |
2005-03-16 |
Lilly Co Eli |
6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist
|
WO2005019168A2
(en)
|
2003-08-20 |
2005-03-03 |
Pfizer Products Inc. |
Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
|
MXPA06002778A
(es)
|
2003-09-09 |
2006-06-14 |
Pfizer Prod Inc |
Combinacion de inhibidores de recaptacion de serotonina e inhibidores de recaptacion de norepinefrina.
|
JP2007505106A
(ja)
|
2003-09-09 |
2007-03-08 |
イーライ リリー アンド カンパニー |
アゼピン、オキサゼピン、およびチアゼピンの置換ピペラジン
|
GB0322140D0
(en)
|
2003-09-22 |
2003-10-22 |
Pfizer Ltd |
Combinations
|
US7244843B2
(en)
|
2003-10-07 |
2007-07-17 |
Bristol-Myers Squibb Company |
Modulators of serotonin receptors
|
ATE430729T1
(de)
|
2003-10-08 |
2009-05-15 |
Lilly Co Eli |
Pyrrol- und pyrazolderivate als potentiatoren von glutamatrezeptoren
|
WO2005035523A1
(en)
|
2003-10-08 |
2005-04-21 |
Pfizer Japan Inc. |
Fused lactam compounds
|
US20050080100A1
(en)
|
2003-10-09 |
2005-04-14 |
Pfizer Inc |
Pyridylamino compounds and methods of use thereof
|
WO2005039580A1
(en)
|
2003-10-16 |
2005-05-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an acetylcholinesterase inhibitor
|
BRPI0415459A
(pt)
|
2003-10-16 |
2006-12-19 |
Pfizer Prod Inc |
preparação de derivados de 3-azabiciclo[3.1.0]hexano
|
EP1689704A2
(en)
|
2003-10-21 |
2006-08-16 |
CoLucid Pharmaceuticals, Inc. |
Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
|
US7671072B2
(en)
|
2003-11-26 |
2010-03-02 |
Pfizer Inc. |
Aminopyrazole derivatives as GSK-3 inhibitors
|
WO2005051488A1
(en)
|
2003-11-26 |
2005-06-09 |
Pfizer Products Inc. |
Combination of dopamine agonists and monoamine reuptake inhibitors
|
WO2005053701A1
(en)
|
2003-11-26 |
2005-06-16 |
Pfizer Products Inc. |
Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
|
EP1706376B1
(en)
|
2003-12-02 |
2009-03-04 |
UCB Pharma, S.A. |
Imidazole derivatives, processes for preparing them and their uses
|
US20070015786A1
(en)
|
2003-12-12 |
2007-01-18 |
Eli Lily And Company |
Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition
|
US20050227980A1
(en)
|
2003-12-15 |
2005-10-13 |
Pfizer Inc. |
Aralkyl and aralkylidene heterocyclic lactam and imides
|
EP1697353A2
(en)
|
2003-12-15 |
2006-09-06 |
Pfizer Products Incorporated |
Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
|
BRPI0417687A
(pt)
|
2003-12-19 |
2007-04-03 |
Pfizer |
derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
|
TW200522944A
(en)
|
2003-12-23 |
2005-07-16 |
Lilly Co Eli |
CB1 modulator compounds
|
WO2005063296A2
(en)
|
2003-12-23 |
2005-07-14 |
Pfizer Products Inc. |
Therapeutic combination for cognition enhancement and psychotic disorders
|
US20050171095A1
(en)
|
2004-01-06 |
2005-08-04 |
Pfizer Inc |
Combination of CRF antagonists and 5-HT1B receptor antagonists
|
ATE552251T1
(de)
|
2004-01-09 |
2012-04-15 |
Lilly Co Eli |
Thiophen- und furanverbindungen
|
US20050222123A1
(en)
|
2004-01-27 |
2005-10-06 |
North Shore-Long Island Jewish Research Institute |
Cholinesterase inhibitors for treating inflammation
|
WO2005082370A1
(en)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
|
WO2005082372A1
(en)
|
2004-01-29 |
2005-09-09 |
Pfizer Products Inc. |
COMBINATION OF γ-AMINOBUTYRIC ACID MODULATORS AND 5-HT 1B RECEPTOR ANTAGONISTS
|
WO2005074535A2
(en)
|
2004-01-30 |
2005-08-18 |
Eisai Co., Ltd. |
Cholinesterase inhibitors for spinal cord disorders
|
EP1720847A1
(en)
|
2004-02-02 |
2006-11-15 |
Pfizer Products Incorporated |
Histamine-3 receptor modulators
|
EP1727538A2
(en)
|
2004-02-13 |
2006-12-06 |
Neuromolecular Inc. |
Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders
|
CN1917882A
(zh)
|
2004-02-13 |
2007-02-21 |
辉瑞产品公司 |
非典型抗精神病药物与促肾上腺皮质激素释放因子拮抗剂的治疗剂组合
|
US20050182044A1
(en)
|
2004-02-17 |
2005-08-18 |
Bruinsma Gosse B. |
Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate
|
DK1720836T3
(da)
|
2004-02-25 |
2014-05-05 |
Lilly Co Eli |
6-substituerede 2,3,4,5-tetrahydro-1h-benzo [d]azepiner som 5-ht2c-receptoragonister
|
GB0405200D0
(en)
|
2004-03-08 |
2004-04-21 |
Pfizer Ltd |
Combinations comprising alpha-2-delta ligands
|
US20060148807A1
(en)
|
2004-03-12 |
2006-07-06 |
Pfizer Inc |
Pyrrolo[1,2b]pyridazine compounds and their uses
|
US20060166998A1
(en)
|
2004-03-12 |
2006-07-27 |
Pfizer Inc |
Pyrrolo[1,2-B]pyridazine compounds and their uses
|
AP2006003726A0
(en)
|
2004-03-17 |
2006-10-31 |
Pfizer Prod Inc |
Novel benzyl(idene)-lactam derivatives
|
EP1740172A4
(en)
|
2004-03-19 |
2007-10-10 |
Axonyx Inc |
ACETYLCHOLINESTERASE INHIBITORS AND N-METHYL-D-ASPARTATE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DISORDER
|
WO2005100334A1
(en)
|
2004-04-14 |
2005-10-27 |
Pfizer Products Inc. |
Dipeptidyl peptidase-iv inhibitors
|
WO2005102272A2
(en)
|
2004-04-21 |
2005-11-03 |
Pfizer Products Inc. |
Sustained-release dosage forms for cabergoline
|
EP1740573A1
(en)
|
2004-04-22 |
2007-01-10 |
Eli Lilly And Company |
Amides as bace inhibitors
|
US20050245543A1
(en)
|
2004-04-30 |
2005-11-03 |
Pfizer Inc |
Histamine-3 receptor antagonists
|
MXPA06013163A
(es)
|
2004-05-11 |
2007-02-13 |
Pfizer Prod Inc |
Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
|
JP2008500381A
(ja)
|
2004-05-21 |
2008-01-10 |
ファイザー・プロダクツ・インク |
ピラジニルメチルラクタム誘導体
|
BRPI0511195A
(pt)
|
2004-05-21 |
2007-12-04 |
Pfizer Prod Inc |
tetraidronaftilpiperazinas como antagonistas da 5-ht1b, agonistas inversos e agonistas parciais
|
US20070212428A1
(en)
|
2004-06-04 |
2007-09-13 |
Mood Management Sciences, Inc. |
Methods and compositions for treating mood disorder
|
CA2569411A1
(en)
|
2004-06-04 |
2005-12-22 |
Mood Management Sciences, Llc |
Methods and compositions for treating mood disorder
|
US7612215B2
(en)
|
2004-06-11 |
2009-11-03 |
Ucb Pharma, S.A. |
Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
|
WO2006000914A1
(en)
|
2004-06-22 |
2006-01-05 |
Pfizer Products Inc. |
Diazabicyclic histamine-3 receptor antagonists
|
CA2571443A1
(en)
|
2004-06-25 |
2006-01-05 |
Pfizer Products Inc. |
Pyridyl piperazines for the treatment of cns disorders
|
US7618980B2
(en)
|
2004-07-14 |
2009-11-17 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)quinolines as 5HT ligands
|
US7572805B2
(en)
|
2004-07-14 |
2009-08-11 |
Bristol-Myers Squibb Company |
Pyrrolo(oxo)isoquinolines as 5HT ligands
|
US20060014733A1
(en)
|
2004-07-19 |
2006-01-19 |
Pfizer Inc |
Histamine-3 agonists and antagonists
|
WO2006011043A1
(en)
|
2004-07-21 |
2006-02-02 |
Pfizer Products Inc. |
Histamine-3 receptor antagonists
|
MX2007001615A
(es)
|
2004-08-09 |
2007-04-10 |
Warner Lambert Co |
Nuevos inhibidores de la recaptacion de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central.
|
BRPI0514820A
(pt)
|
2004-09-01 |
2008-06-24 |
Pfizer Prod Inc |
antagonistas de receptor de histamina-3 amina azabicìclicos
|
JP2008512438A
(ja)
|
2004-09-10 |
2008-04-24 |
ファイザー・プロダクツ・インク |
療法用ジフェニルエーテル系リガンド
|
CA2580034A1
(en)
|
2004-09-10 |
2006-03-16 |
Pfizer Products Inc. |
Methods of treating mood disorders using benzisoxazole containing diazabicyclic compounds
|
US20060063707A1
(en)
|
2004-09-17 |
2006-03-23 |
Lifelike Biomatic, Inc. |
Compositions for enhancing memory and methods therefor
|
US20060069087A1
(en)
|
2004-09-27 |
2006-03-30 |
Pfizer Inc |
Histamine-3 receptor antagonists
|
WO2006040688A2
(en)
|
2004-10-12 |
2006-04-20 |
Ernir Snorrason |
Inhibitors of acetylcholinesterase for treating skin diseases
|
EP1802301A1
(en)
|
2004-10-15 |
2007-07-04 |
Pfizer Inc. |
Treatment of bipolar disorders and associated symptoms
|
ATE504582T1
(de)
|
2004-10-18 |
2011-04-15 |
Lilly Co Eli |
Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
|
BRPI0516602A
(pt)
|
2004-10-18 |
2008-09-16 |
Lilly Co Eli |
composto, e, composição farmacêutica
|
WO2006060082A1
(en)
|
2004-10-22 |
2006-06-08 |
THE GOVERNMENT OF THE U.S.A. as represented by THE SEC., DEPT. OF HEALTH & HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH |
Tricyclic compounds, preparation thereof and use thereof as cholinesterase activity inhibitors
|
WO2006046131A1
(en)
|
2004-10-29 |
2006-05-04 |
Pfizer Products Inc. |
Tetralin histamine-3 receptor antagonists
|
WO2006048727A1
(en)
|
2004-11-02 |
2006-05-11 |
Pfizer Products Inc. |
Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
|
CA2587461A1
(en)
|
2004-11-15 |
2006-05-18 |
Pfizer Products Inc. |
Azabenzoxazoles for the treatment of cns disorders
|
EP1814887A1
(en)
|
2004-11-15 |
2007-08-08 |
Pfizer Products Incorporated |
Azabenzoxazoles for the treatment of cns disorders
|
WO2006056873A2
(en)
|
2004-11-29 |
2006-06-01 |
Warner-Lambert Company Llc |
Therapeutic pyrazolo[3,4-b] pyridines and indazoles
|
DE602005006840D1
(de)
|
2004-12-07 |
2008-06-26 |
Pfizer Prod Inc |
1,2,3,3a;8,8a-hexahydro-2,7a-diazacyclopentaäaüinden-7-onderivate, die sich an neuronale nikotinische acetylcholinspezifische rezeptorstellen binden und zur modulation der cholinergen funktion und zur behandlung von suchterkrankungen eignen
|
JP2008525439A
(ja)
|
2004-12-23 |
2008-07-17 |
ボイジャー・ファーマシューティカル・コーポレーション |
アルツハイマー病の治療のための酢酸ロイプロリド及びアセチルコリンエステラーゼインヒビターまたはnmdaレセプターアゴニスト
|
WO2006070394A1
(en)
|
2004-12-28 |
2006-07-06 |
Council Of Scientific And Industrial Research |
Substituted carbamic acid quinolin-6-yl esters useful as acetylcholinesterase inhibitors
|
US20060183763A1
(en)
|
2004-12-31 |
2006-08-17 |
Pfizer Inc |
Novel pyrrolidyl derivatives of heteroaromatic compounds
|
EP1838716B1
(en)
|
2005-01-05 |
2011-06-01 |
Eli Lilly And Company |
Olanzapine pamoate dihydrate
|
ZA200707250B
(en)
|
2005-01-27 |
2009-06-24 |
Alembic Ltd |
Extended release formulation of levetiracetam
|
EP1846410B1
(en)
|
2005-02-10 |
2009-01-21 |
Bristol-Myers Squibb Company |
Dihydroquinazolinones as 5ht modulators
|
FR2881618B1
(fr)
|
2005-02-10 |
2007-04-13 |
Centre Nat Rech Scient |
Utilisation de composes derives de pyrimidinetrione en tant qu'inhibiteurs de l'acetylcholinesterase, compositions contenant ces derives et leurs utilisations en tant qu'insecticides
|
WO2006088716A1
(en)
|
2005-02-15 |
2006-08-24 |
Eli Lilly And Company |
Substituted tetralins as selective estrogen receptor-beta agonists
|
US20070298098A1
(en)
|
2005-02-16 |
2007-12-27 |
Elan Pharma International Limited |
Controlled Release Compositions Comprising Levetiracetam
|
WO2006090272A1
(en)
|
2005-02-22 |
2006-08-31 |
Warner-Lambert Company Llc |
Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
|
EP1909770B1
(en)
|
2005-02-22 |
2013-03-20 |
Sun Pharmaceutical Industries Limited |
Oral controlled release composition containing levetiracetam
|
WO2006090273A2
(en)
|
2005-02-22 |
2006-08-31 |
Warner-Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
|
US8216611B2
(en)
|
2005-03-30 |
2012-07-10 |
Mylan Pharmaceuticals Ulc |
Combined-step process for pharmaceutical compositions
|
EA200701856A1
(ru)
|
2005-04-01 |
2008-02-28 |
Уорнер-Ламберт Компани Ллс |
Тетрагидропиридоазепин-8-оны и родственные соединения для лечения шизофрении
|
KR101406456B1
(ko)
|
2005-04-06 |
2014-06-20 |
아다마스 파마슈티칼스, 인코포레이티드 |
Cns 장애의 치료를 위한 방법 및 조성물
|
WO2006106416A1
(en)
|
2005-04-08 |
2006-10-12 |
Pfizer Products Inc. |
PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
|
JP4193949B2
(ja)
|
2005-04-08 |
2008-12-10 |
ファイザー・プロダクツ・インク |
I型グリシン輸送阻害剤としての二環式[3.1.0]ヘテロアリールアミド
|
US20080305161A1
(en)
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
US7741358B2
(en)
|
2005-04-14 |
2010-06-22 |
N.V. Organon |
Crystal form of asenapine maleate
|
US20060241144A1
(en)
|
2005-04-20 |
2006-10-26 |
Albert Cha |
Method for treating apathy syndrome
|
WO2006116401A1
(en)
|
2005-04-28 |
2006-11-02 |
Bristol-Myers Squibb Company |
C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
|
US20060276412A1
(en)
*
|
2005-05-31 |
2006-12-07 |
Gary Tollefson |
Methods and compositions for managing psychotic disorders
|
EP1912966A2
(en)
|
2005-06-01 |
2008-04-23 |
Ucb, S.A. |
2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
|
EP1731149A1
(en)
|
2005-06-08 |
2006-12-13 |
Ucb S.A. |
Use of 2-oxo-1-pyrrolidone derivatives for the treatment of diseases characterized by progressive myoclonic epilepsy
|
CA2607499C
(en)
|
2005-06-22 |
2010-11-30 |
Pfizer Products Inc. |
Histamine-3 receptor antagonists
|
US20070015763A1
(en)
|
2005-07-12 |
2007-01-18 |
Pfizer Inc |
Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
|
JP2009502959A
(ja)
|
2005-07-28 |
2009-01-29 |
ブリストル−マイヤーズ スクイブ カンパニー |
セロトニン受容体アゴニストおよびアンタゴニストとしての置換テトラヒドロ−1h−ピリド[4,3,b]インドール
|
EP2682481A3
(en)
|
2005-08-03 |
2014-09-17 |
The Johns-Hopkins University |
Methods for characterizing and treating cognitive impairment in aging and disease
|
WO2007017750A1
(en)
|
2005-08-08 |
2007-02-15 |
Pfizer Products Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane
|
US7795436B2
(en)
|
2005-08-24 |
2010-09-14 |
Bristol-Myers Squibb Company |
Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
|
WO2007026219A2
(en)
|
2005-08-31 |
2007-03-08 |
Pfizer Products Inc. |
Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
|
GB0517740D0
(en)
|
2005-08-31 |
2005-10-12 |
Novartis Ag |
Organic compounds
|
WO2007028132A2
(en)
|
2005-09-01 |
2007-03-08 |
Eli Lilly And Company |
6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
|
JP5237810B2
(ja)
|
2005-09-01 |
2013-07-17 |
イーライ リリー アンド カンパニー |
5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン
|
AU2006287202B2
(en)
|
2005-09-01 |
2013-01-24 |
Eli Lilly And Company |
6-arylalkylamino- 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2c receptor agonists
|
PT1924560E
(pt)
|
2005-09-01 |
2009-10-23 |
Lilly Co Eli |
2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c
|
US20090215857A1
(en)
|
2005-09-13 |
2009-08-27 |
Pfizer Products Inc. |
Therapeutic Pyrrolidines
|
AR056155A1
(es)
|
2005-10-26 |
2007-09-19 |
Bristol Myers Squibb Co |
Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
|
US7745447B2
(en)
|
2005-10-26 |
2010-06-29 |
Bristol-Myers Squibb Company |
Substituted thieno[3,2-D]pyrimidines as non-basic melanin concentrating hormone receptor-1 antagonists
|
US8158673B2
(en)
|
2005-10-27 |
2012-04-17 |
Pfizer Inc. |
Histamine-3 receptor antagonists
|
WO2007057742A2
(en)
|
2005-11-18 |
2007-05-24 |
Pfizer Products Inc. |
Novel piperazinone derivatives
|
WO2007063385A2
(en)
|
2005-12-01 |
2007-06-07 |
Pfizer Products Inc. |
Spirocyclic amine histamine-3 receptor antagonists
|
CA2631885A1
(en)
|
2005-12-07 |
2007-06-14 |
Ucb Pharma, S.A. |
Xanthine derivatives, processes for preparing them and their uses
|
WO2007069053A1
(en)
|
2005-12-14 |
2007-06-21 |
Pfizer Products Inc. |
Benzimidazole antagonists of the h-3 receptor
|
NL2000397C2
(nl)
|
2006-01-05 |
2007-10-30 |
Pfizer Prod Inc |
Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
|
CA2635439A1
(en)
|
2006-01-27 |
2007-08-02 |
Pfizer Products Inc. |
Aminophthalazine derivative compounds
|
WO2007088450A2
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Chromane antagonist of the h-3 receptor
|
WO2007088462A1
(en)
|
2006-02-01 |
2007-08-09 |
Pfizer Products Inc. |
Spirochromane antagonists of the h-3 receptor
|
US7553836B2
(en)
|
2006-02-06 |
2009-06-30 |
Bristol-Myers Squibb Company |
Melanin concentrating hormone receptor-1 antagonists
|
JP2009527542A
(ja)
|
2006-02-23 |
2009-07-30 |
ファイザー・プロダクツ・インク |
Pde10阻害薬としての置換キナゾリン
|
WO2007099423A1
(en)
|
2006-03-02 |
2007-09-07 |
Pfizer Products Inc. |
1-pyrrolidine indane derivatives as histamine-3 receptor antagonists
|
AU2007223036A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
US20100216734A1
(en)
*
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
JP2009539762A
(ja)
|
2006-03-13 |
2009-11-19 |
ファイザー・プロダクツ・インク |
H3受容体のテトラリン拮抗薬
|
JP2009531323A
(ja)
|
2006-03-20 |
2009-09-03 |
カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ |
アセチルコリンエステラーゼ阻害剤として有用な薬剤組成物
|
US20070224636A1
(en)
|
2006-03-24 |
2007-09-27 |
Pfizer Inc |
Pyrrolo[1,2b]pyridazine compounds and their uses
|
CA2650711A1
(en)
|
2006-04-28 |
2007-11-08 |
Northwestern University |
Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
|
US20090176829A1
(en)
|
2006-05-02 |
2009-07-09 |
Pfizer Inc |
Bicyclic heteroaryl compounds as pde10 inhibitors
|
AU2007249435A1
(en)
|
2006-05-09 |
2007-11-22 |
Braincells, Inc. |
5 HT receptor mediated neurogenesis
|
US7858611B2
(en)
|
2006-05-09 |
2010-12-28 |
Braincells Inc. |
Neurogenesis by modulating angiotensin
|
WO2007138431A2
(en)
|
2006-05-30 |
2007-12-06 |
Pfizer Products Inc. |
Azabicyclic ether histamine-3 antagonists
|
ES2444009T3
(es)
|
2006-06-08 |
2014-02-21 |
Ucb Pharma, S.A. |
Co-cristales de pirrolidinonas
|
CA2654394A1
(en)
|
2006-06-26 |
2008-01-03 |
Pfizer Products Inc. |
Tricyclic heteroaryl compounds as pde10 inhibitors
|
US20080014264A1
(en)
|
2006-07-13 |
2008-01-17 |
Ucb, S.A. |
Novel pharmaceutical compositions comprising levetiracetam
|
WO2008010073A1
(en)
|
2006-07-14 |
2008-01-24 |
Pfizer Products Inc. |
Tartrate salt of (7s)-7-[(5-fluoro-2-methyl-benzyl)oxy]-2-[(2r)-2-methylpiperazin-1-yl]-6,7-dihydro-5h-cyclopenta[b]pyridine
|
WO2008015516A1
(en)
|
2006-07-28 |
2008-02-07 |
Pfizer Products Inc. |
Fused tricyclic heterocycles for the treatment of schizophrenia
|
US20080045512A1
(en)
|
2006-08-09 |
2008-02-21 |
Pfizer Inc. |
Benzoate salt of 4-(5-methyl-oxazolo[4,5-b]-pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane
|
WO2008020302A2
(en)
|
2006-08-17 |
2008-02-21 |
Pfizer Products Inc. |
Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
|
EP2051696A2
(en)
|
2006-08-18 |
2009-04-29 |
Morton Grove Pharmaceuticals, Inc. |
Stable liquid levetiracetam compositions and methods
|
WO2008020306A2
(en)
|
2006-08-18 |
2008-02-21 |
Pfizer Products Inc. |
Isoindole derivatives
|
WO2008026046A1
(en)
|
2006-08-30 |
2008-03-06 |
Pfizer Products Inc. |
Morpholine d3 dopamine antagonists
|
JP2010503654A
(ja)
|
2006-09-12 |
2010-02-04 |
ファイザー・プロダクツ・インク |
ベンゾイミダゾロン誘導体
|
WO2008062446A2
(en)
|
2006-09-14 |
2008-05-29 |
Alembic Limited |
An extended release composition of levetiracetam, which exhibits no adverse food effect
|
WO2008036846A2
(en)
|
2006-09-22 |
2008-03-27 |
Braincells, Inc. |
Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
|
AR063497A1
(es)
|
2006-10-23 |
2009-01-28 |
Lilly Co Eli |
Compuesto de pirrodinil -2-ona, intermediario para la sintesis del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento
|
US20100152108A1
(en)
|
2006-10-27 |
2010-06-17 |
Medivation Neurology, Inc. |
Methods and combination therapies for treating alzheimer's disease
|
WO2008065500A2
(en)
|
2006-11-30 |
2008-06-05 |
Pfizer Products Inc. |
Heteroaryl amides as type i glycine transport inhibitors
|
US8247563B2
(en)
|
2006-12-11 |
2012-08-21 |
Reviva Pharmaceuticals, Inc. |
Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors
|
WO2008074896A1
(en)
|
2006-12-21 |
2008-06-26 |
Prendergast Patrick T |
Compositions and methods for treatment of chronic neurological disorders
|
WO2008084324A1
(en)
|
2007-01-04 |
2008-07-17 |
Pfizer Products Inc. |
Naphthyridinone compound
|
CA2676456C
(en)
|
2007-01-22 |
2012-03-27 |
Pfizer Products Inc. |
Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof
|
EP2125709A2
(en)
|
2007-02-02 |
2009-12-02 |
Colucid Pharmaceuticals, Inc. |
Compounds that inhibit cholinesterase
|
FR2912056B1
(fr)
|
2007-02-05 |
2009-12-18 |
Rd Pharmagal |
Composition a liberation prolongee de levetiracetam et procede de preparation
|
AU2007346591A1
(en)
|
2007-02-07 |
2008-08-14 |
Gosforth Centre (Holdings) Pty Ltd |
Treatment of ADHD
|
MX2009008546A
(es)
|
2007-02-07 |
2009-10-08 |
Pfizer |
Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)carbaldehido como inhibidores de la proteina quinasa c.
|
MX2009010951A
(es)
|
2007-04-12 |
2009-10-29 |
Pfizer |
Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c.
|
WO2008134480A1
(en)
|
2007-04-25 |
2008-11-06 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists
|
EP2152262A2
(en)
|
2007-04-27 |
2010-02-17 |
UCB Pharma, S.A. |
New heterocyclic derivatives useful for the treatment of cns disorders
|
WO2008144305A1
(en)
|
2007-05-18 |
2008-11-27 |
Janssen Pharmaceutica N.V. |
Diaryl-substituted tetrahydroisoquinolines as histamine h3 receptor and serotonin transporter modulators
|
US20090011994A1
(en)
|
2007-07-06 |
2009-01-08 |
Bristol-Myers Squibb Company |
Non-basic melanin concentrating hormone receptor-1 antagonists and methods
|
RU2339620C1
(ru)
|
2007-07-09 |
2008-11-27 |
Общество С Ограниченной Ответственностью "Фармвинг" |
Оксалат n, n-диметил-2-n, n-диметиламинометилпиридил-3-карбамат, обладающий антихолинэстеразной активностью и способностью улучшать когнитивные функции
|
EP2164489A2
(en)
|
2007-07-13 |
2010-03-24 |
Eisai R&D Management Co., Ltd. |
Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
|
US20090030403A1
(en)
|
2007-07-27 |
2009-01-29 |
Leyde Kent W |
Methods and Systems for Attenuating the Tolerance Response to a Drug
|
WO2009038412A2
(en)
|
2007-09-21 |
2009-03-26 |
Lg Life Sciences, Ltd. |
Beta-secretase inhibiting compounds
|
US20090176740A1
(en)
|
2007-11-30 |
2009-07-09 |
Phillips Ii Dauglas James |
Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine
|
CN101939306A
(zh)
|
2007-12-07 |
2011-01-05 |
美国辉瑞有限公司 |
反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐
|
US20100297181A1
(en)
*
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
PL2252581T3
(pl)
|
2008-01-22 |
2012-10-31 |
Lilly Co Eli |
Selektywny antagonista receptora opioidowego kappa
|
JP2011511056A
(ja)
|
2008-02-05 |
2011-04-07 |
ファイザー・インク |
Cns障害および代謝障害治療のためのピリジニルアミド
|
PL2273975T3
(pl)
|
2008-03-03 |
2014-09-30 |
Ucb Pharma Sa |
Roztwory farmaceutyczne, sposoby wytwarzania i zastosowania terapeutyczne
|
JP2011518143A
(ja)
|
2008-04-17 |
2011-06-23 |
ファイザー・インク |
Faah阻害剤として有用なエーテルベンジリデンピペリジンアリールカルボキサミド化合物
|
JP5539322B2
(ja)
|
2008-04-22 |
2014-07-02 |
イーライ リリー アンド カンパニー |
Cb−1リガンドとしての1,5−ジフェニル−ピロリジン−2−オン化合物
|
DK2280961T3
(da)
|
2008-04-22 |
2012-08-27 |
Lilly Co Eli |
1,5-diphenyl-pyrrolidin-2-on-forbindelser som cb-1-ligander
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
US20110212944A1
(en)
|
2008-07-01 |
2011-09-01 |
Julie Liu |
2-oxo-1-pyrrolidine derivatives
|
JP2010024156A
(ja)
|
2008-07-16 |
2010-02-04 |
Ucb Pharma Sa |
レベチラセタムを含む医薬組成物
|
TW201006801A
(en)
|
2008-07-18 |
2010-02-16 |
Lilly Co Eli |
Imidazole carboxamides
|
US7932256B2
(en)
|
2008-07-31 |
2011-04-26 |
Bristol-Myers Squibb Company |
(S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
|
WO2010015029A1
(en)
|
2008-08-06 |
2010-02-11 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating psychiatric disorders
|
CN107243007A
(zh)
|
2008-10-16 |
2017-10-13 |
约翰斯.霍普金斯大学 |
改善认知功能的方法和组合物
|
US20100113465A1
(en)
|
2008-10-30 |
2010-05-06 |
Pfizer Inc. |
7-azaspiro[3.5]nonane-7-carboxamide compounds
|
US9125898B2
(en)
|
2008-11-14 |
2015-09-08 |
Neurotune Ag |
Acetam derivatives for pain relief
|
US20100125094A1
(en)
|
2008-11-17 |
2010-05-20 |
Auspex Pharmaceuticals, Inc. |
Pyrrolidinyl modulators of nicotinic acetylcholine receptors
|
DK2358360T3
(en)
|
2008-11-18 |
2016-12-12 |
Ucb Biopharma Sprl |
EXTENDED release formulations comprising one 2-OXO-1 PYRROLIDIN DERIVATIVE
|
WO2010058318A1
(en)
|
2008-11-21 |
2010-05-27 |
Pfizer Inc. |
1-oxa-8-azaspiro [4, 5 ] decane- 8 -carboxamide compounds as faah inhibitors
|
US20100172979A1
(en)
|
2008-12-24 |
2010-07-08 |
Zhongshui Yu |
Controlled-release formulations
|
AU2010209790B2
(en)
|
2009-01-29 |
2014-01-16 |
Ucb Pharma, S.A. |
Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
|
WO2010089372A1
(en)
|
2009-02-09 |
2010-08-12 |
Ucb Pharma, S.A. |
Pharmaceutical compositions comprising brivaracetam
|
WO2010104818A1
(en)
|
2009-03-09 |
2010-09-16 |
Bristol-Myers Squibb Company |
Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
EP2405913A1
(en)
|
2009-03-09 |
2012-01-18 |
Bristol-Myers Squibb Company |
Pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
|
WO2010111080A2
(en)
|
2009-03-27 |
2010-09-30 |
Eli Lilly And Company |
Optimized treatment of schizophrenia
|
US8846411B2
(en)
|
2009-06-11 |
2014-09-30 |
Microgenics Corporation |
Derivatives, reagents, and immunoassay for detecting levetiracetam
|
CA2763960C
(en)
|
2009-06-18 |
2014-07-08 |
Pfizer Inc. |
Bicyclic and tricyclic compounds as kat ii inhibitors
|
US20120171125A1
(en)
|
2009-08-07 |
2012-07-05 |
Ucb Pharma, S.A. |
Methods for Enhancing the Cognitive Function
|
CN101647789B
(zh)
|
2009-09-01 |
2011-08-17 |
天津药物研究院药业有限责任公司 |
左乙拉西坦缓释微丸胶囊制剂
|
JP5827952B2
(ja)
|
2009-10-09 |
2015-12-02 |
ユンジン・ファーム・カンパニー・リミテッドYungjin Pharm. Co. Ltd. |
速効性と持続性を同時に有する薬剤学的組成物
|
US20110262442A1
(en)
*
|
2009-11-06 |
2011-10-27 |
Adenios, Inc. |
Compositions for treating cns disorders
|
UA107943C2
(en)
|
2009-11-16 |
2015-03-10 |
Lilly Co Eli |
Compounds of spiropiperidines as antagonists of the orl-1 receptors
|
CA2781041C
(en)
|
2009-11-16 |
2015-01-06 |
Eli Lilly And Company |
Spiropiperidine compounds as orl-1 receptor antagonists
|
AR079343A1
(es)
|
2009-12-21 |
2012-01-18 |
Lilly Co Eli |
Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico
|
CA2789014C
(en)
|
2010-02-09 |
2019-01-15 |
Michela Gallagher |
Methods and compositions for improving cognitive function
|
WO2011143721A1
(en)
|
2010-05-21 |
2011-11-24 |
Gosforth Centre (Holdings) Pty Ltd |
Compositions and methods for treating neurodegenerative disorders
|
SG186409A1
(en)
|
2010-07-08 |
2013-02-28 |
Pfizer |
Piperidinyl pyrimidine amides as kv7 potassium channel openers
|
EP2619202A1
(en)
|
2010-09-21 |
2013-07-31 |
Pfizer Inc |
Pyridmidones for treatment of potassium channel related diseases
|
WO2012056402A2
(en)
|
2010-10-26 |
2012-05-03 |
Alpharma Pharmaceuticals, Llc |
Formulations and methods for attenuating respiratory depression induced by opioid overdose
|
KR20120055313A
(ko)
|
2010-11-23 |
2012-05-31 |
주식회사 바이오파마티스 |
레베티라세탐 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법
|
CN103228631B
(zh)
|
2010-12-01 |
2015-04-29 |
辉瑞大药厂 |
Kat ii 抑制剂
|
JP2013544277A
(ja)
|
2010-12-01 |
2013-12-12 |
ファイザー・インク |
Katii阻害剤
|
US20120214859A1
(en)
*
|
2011-02-09 |
2012-08-23 |
Michela Gallagher |
Methods and compositions for improving cognitive function
|
JP5543039B2
(ja)
|
2011-02-23 |
2014-07-09 |
ファイザー・インク |
神経障害治療のためのイミダゾ[5,1−f][1,2,4]トリアジン
|
DE102011103270A1
(de)
|
2011-05-26 |
2012-11-29 |
Stada Arzneimittel Ag |
Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten
|
GB201111712D0
(en)
|
2011-07-08 |
2011-08-24 |
Gosforth Ct Holdings Pty Ltd |
Pharmaceutical compositions
|
JP6440625B2
(ja)
|
2012-11-14 |
2018-12-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
精神分裂病を処置するための方法および組成物
|
CA2904767C
(en)
|
2013-03-15 |
2022-06-21 |
Agenebio, Inc. |
Methods and compositions for improving cognitive function
|
US20160030391A1
(en)
|
2013-03-15 |
2016-02-04 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
US10806717B2
(en)
|
2013-03-15 |
2020-10-20 |
The Johns Hopkins University |
Methods and compositions for improving cognitive function
|
CN107810002B
(zh)
|
2015-05-22 |
2021-01-05 |
艾吉因生物股份有限公司 |
左乙拉西坦的延时释放药物组合物
|